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Overview of the thesis 
The overall aim of this thesis was to investigate the role of microRNAs (miRNAs) during 
dedifferentiation and chondrogenic differentiation of articular chondrocytes (ACs) and 
mesenchymal stem cells (MSCs), respectively. miRNAs are small RNA molecules that 
regulate gene expression in a sequence-specific manner by binding to complementary mRNA 
sequences often leading to degradation of the mRNA or translational repression. In other 
situations, miRNAs may enhance gene expression. When this thesis was begun, there were 
relatively few studies on cartilage biology that involved miRNAs, and no studies had 
investigated global miRNA changes during dedifferentiation of human ACs or chondrogenic 
differentiation of human MSCs.  
  As miRNAs are regarded to be important regulators of gene expression in most cell 
types, we decided to perform a global miRNA analysis of both ACs and MSCs to identify 
miRNAs that were important for cartilage biology and to investigate their function and 
identify their targets. In paper I and II we identified miR-140 as an important miRNA during 
dedifferentiation of ACs and chondrogenic differentiation of MSCs. In vivo studies have 
previously identified miR-140 as an important miRNA for cartilage development and 
homeostasis, but the mechanism has not been fully understood. In paper II, we show that 
miR-140 positively regulated the master transcription factor of chondrogenesis SOX9 and the 
proteoglycan ACAN at the post-transcriptional level. The results provided here may explain 
the profound effect of miR-140 in cartilage biology. 
 In paper III, we performed gain- and loss-of-function studies using transient 
transfection of small synthetic double-stranded microRNA mimics (smiRs) and inhibitors. 
Surprisingly, transfection of smiR-145, but not any of the other synthetic molecules tested, 
lead to a strong immune response in both MSCs and ACs. The immune response was not a 
result of smiR-145 regulating its target genes, but a result of the cell responding to smiR-145 
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as a foreign molecule. Such immune responses complicate the interpretation of the results. In 
paper III, we investigated this phenomenon and identified the receptor responsible for the 
immune response. Induction of the immune response required liposome delivery of smiR-145, 
as no immune gene changes were observed after delivery of smiR-145 directly into the 
cytosol using electroporation. This insight is important for researchers to avoid unexpected 
results from transient transfection experiments in vitro and unwanted immune responses 
following the use of liposome transfection reagents in vivo.  
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RUNX2  runt-related transcription factor 2 
siRNAs  small interfering RNAs  
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Introduction 
 
Cartilage 
Cartilage is a connective tissue found in different parts of the body, such as the ear, 
intervertebral discs and in the joints. There are three different types of cartilage: elastic 
cartilage, fibrocartilage and hyaline cartilage. All three types consist of water and an 
extracellular matrix (ECM) that gives the cartilage its unique properties. However, the three 
types of cartilage consist of different types and amounts of ECM molecules that are organised 
in different ways, giving each type of cartilage unique properties to fulfil its function in 
different parts of the body. In this thesis, the focus is on articular cartilage, the hyaline 
cartilage that covers the articular surfaces of bones. 
Articular cartilage 
The main function of articular cartilage is to allow for smooth movement of our bones against 
each other and to absorb and transmit the mechanical load resulting from daily activities, such 
as walking or sports activities. Articular cartilage is a highly specialised tissue. It has no blood 
supply, it is not innervated, and it obtains nutrients mainly by diffusion from the synovial 
fluid inside the joint (1). Articular cartilage is approximately 2-2.5 mm thick (with anatomical 
and topographical variations) (2,3), consisting mainly of water, collagens, proteoglycans, 
glycosaminoglycans (GAGs) and smaller amounts of glycoproteins and non-collagenous 
molecules (4). The cells in articular cartilage are called articular chondrocytes (ACs), and they 
make up approximately 2% of the tissue volume (3).  
The scope of this thesis does not allow a detailed, complete description of all the 
molecules of the ECM, their function or their arrangement within the ECM. A general 
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description of the most important ECM molecules and their structure and function will be 
given below. For a more comprehensive description, the following references are 
recommended(4,5).  
The articular cartilage is organised into four different zones based on structural and 
functional differences: 1) the superficial zone (SZ), 2) the middle zone (MZ), 3) the deep zone 
(DZ) and 4) the calcified zone (CZ) (Figure 1).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of adult human articular cartilage showing the zonal and regional organisation of 
the ECM and the relative thickness of the collagen fibrils (from Poole et al., 2001)(5). 
 
The SZ is the surface that lines the synovial joint and is in direct contact with the 
synovial fluid. At the SZ, the cells are flattened and have a fibroblastoid shape and produce 
thin collagen fibrils that are oriented horizontally to the articular surface (6). It has been 
suggested that the SZ also contain progenitor cells/stem cells that are responsible for growth 
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during development (7). In general, there are small amounts of proteoglycans in the SZ, but the 
chondrocytes produce proteoglycan 4 (also called lubricin) that reduces friction and thereby 
functions as a lubricant at the articular surface (5,8). The MZ contains more proteoglycans and 
has a lower cell density than the SZ. The cells are more rounded, and the collagen fibrils are 
thicker and more randomly distributed. The DZ has the lowest cell and collagen density, but it 
has the highest concentration of proteoglycans. The collagen fibrils are thicker and oriented 
more perpendicularly to the surface, and the chondrocytes are arranged into column-like 
structures parallel to the collagen fibrils. Below the DZ is the tide mark, a thin interface that 
separates the non-calcified cartilage from the CZ, which is integrated within the underlying 
subchondral bone. The chondrocytes in the CZ produce the hypertrophic marker type X 
collagen, and they are responsible for the calcification of the ECM. In addition to the zonal 
organisation, there is regional organisation of the ECM (Figure 1). The ECM immediately 
surrounding the chondrocytes is called the pericellular region. A single chondrocyte and its 
pericellular region are called a chondron, which is considered to be the smallest metabolic and 
functional unit of articular cartilage (9). The ECM outside the pericellular region is called the 
territorial region, while the ECM most distant to the cells is referred to as the inter-territorial 
region (4,5,10).  
In articular cartilage, the collagen exists as fibrils that are assembled into large 
collagen fibres. The collagen fibrils consist mainly of type II collagen and small amounts of 
type XI collagen, while type IX collagen decorates the surface of the type II/XI fibrils and is 
thought to mediate interaction with other collagen fibrils and with other ECM molecules  (11). 
The collagen gives the ECM the tensile strength to withstand mechanical stretch, but it also 
serves as a scaffold where other ECM molecules can be incorporated.  The proteoglycan 
aggrecan and the GAG hyaluronic acid (HA, also known as hyaluronan) are some of the other 
important molecules in articular cartilage. Aggrecan aggregates are shown in Figure 2. 
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Several aggrecan proteins are bound perpendicularly to a single HA molecule (blue) in 
association with a cartilage link protein (dark green) that stabilises the binding. The core 
protein of aggrecan (light green) itself contains many negatively charged GAGs (red), mostly 
chondroitin sulfate and smaller amounts of keratin sulfate (12). Due to the high density of 
negative charge associated with the GAGs, osmotically active cations, most importantly Na+, 
are drawn into the tissue and cause water influx. This creates an osmotic pressure that 
withstands compressive forces. Together with the tensile strength created by the collagens, the 
osmotic pressure makes articular cartilage an ideal tissue for load-bearing.   
 
 
 
 
 
 
 
 
 
Figure 2. Aggrecan aggregate. See text for details (from Alberts  et al., 2008)(12). 
 
The ECM molecules also provide cell-matrix interactions by providing attachment points for 
cell surface receptors, such as integrins, CD44 and syndecans (13,14). The binding of the cell 
surface receptors to ECM ligands activates intracellular signalling pathways that can regulate 
different biological processes, including cell differentiation, proliferation, shape, orientation, 
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movement and survival (12,14). The ECM also binds growth factors and cytokines and can 
serve as a reservoir that regulates the activity of these important signalling molecules (15).  
 
Chondrogenesis and endochondral bone formation 
During development, the articular cartilage is formed through a complex, tightly regulated 
process called chondrogenesis. Most of what is known about chondrogenesis comes from in 
vivo studies in chickens and mice. During the development of the long bones, cartilage is 
formed first and serves as a template for the future bone. Later, through the process of 
endochondral bone formation (or endochondral ossification), the cartilage is replaced by bone, 
except at the end of the bones, where it becomes the articular cartilage. The entire process can 
be divided into five stages (condensation, differentiation, terminal differentiation, 
calcification/hypertrophy and ossification)(16), schematically shown in Figure 3. In vertebrate 
limb development, mesenchymal cells first produce an ECM that is rich in HA and type I and 
II collagen. Then the cells proliferate and migrate to the centre of the limb, leading to 
aggregation of the cells (condensation). During condensation, the cells stop producing type I 
collagen, induce hyaluronidase activity to degrade the HA and express cell adhesion 
molecules such as N-CAM and N-Cadherin. This allows for movement, tight aggregation and 
cell-cell interactions, which possibly trigger chondrogenesis (17) 2004)(18). 
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Figure 3. A schematic representation of chondrogenesis and endochondral bone formation. The figure 
is summarised in the text (from Goldring et al., 2006)(16). 
 
Transforming growth factor beta (TGF-β) is one of the earliest signalling molecules 
expressed during chondrogenesis and is thought to regulate condensation by inducing 
expression of fibronectin, which in turn regulates N-CAM and N-cadherin expression (19,20). 
TGF-β also induces expression of the transcription factor  SRY (sex determining region Y)-
box 9 (SOX9), which is essential for condensation, differentiation and cartilage formation (21-
24). At the end of condensation, syndecans bind to fibronectin and downregulate N-CAM 
expression, which marks the transition from condensation to differentiation (25). During 
differentiation, SOX9, together with L-SOX5 and SOX6, stimulate expression of important 
ECM molecules such as aggrecan, cartilage link protein and type II, IX and XI collagen in a 
bone morphogenetic protein (BMP) signalling-dependent manner (26). The importance of L-
SOX5 and SOX6 for chondrocyte differentiation was shown by generating double mutant 
mice lacking both L-SOX5 and SOX6. These mice had severely underdeveloped cartilage 
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because the chondrocytes were arrested in the condensation stage (27,28). During terminal 
differentiation, the chondrocytes further differentiate and mature as they increase the 
production of types II, IX and XI collagen while the production of fibronectin decreases (29). 
As shown in Figure 3, several factors are involved in this step.  The balance between BMPs 
and FGFs (fibroblast growth factors) seems to regulate proliferation and thereby the rate of 
differentiation/maturation, while parathyroid hormone-like peptide (PTHrP) and Indian 
hedgehog (IHH) signalling regulate the commitment to hypertrophic differentiation (30). At the 
end of terminal differentiation, the mature chondrocytes are thought to be arrested in the cell-
cycle before differentiating into hypertrophic chondrocytes. During hypertrophy, the cells 
increase in size and gene expression shifts from the production of type II collagen to the 
production of type X collagen (hypertrophic marker). Other molecules that are associated with 
hypertrophy are vascular endothelial growth factor (VEGF), which attracts blood vessels, 
matrix metallopeptidase (MMP) 13 and MMP9, which remodel the ECM, possibly by 
degrading type II collagen and aggrecan, and alkaline phosphatase (ALPL), which is involved 
in calcification of the ECM (31-33). The transcription factor runt-related transcription factor 2 
(RUNX2) has an important role in this process as it regulates VEGF, MMP13 and ALPL, 
possibly explaining why endochondral ossification is blocked in RUNX2 knockout mice (34-37). 
At a late stage of hypertrophy, osteoclasts and osteoblasts are recruited, and the mineralised 
cartilage ECM is removed and replaced by bone while the hypertrophic ACs undergo 
apoptosis (16). However, the cartilage at the end of the bones does not undergo 
hypertrophy/ossification and is not replaced by bone; this is the articular cartilage and it 
persists throughout life. The articular cartilage can therefore be referred to as permanent 
cartilage, while the cartilage undergoing ossification can be referred to as transient cartilage 
(38).  The factors regulating the fate of permanent and transient cartilage are not fully known. 
However, the balance of SOX9 and RUNX2 may determine which part of the cartilage 
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become bone and which remains cartilage. SOX9 is not expressed in hypertrophic 
chondrocytes, while RUNX2 is essential for hypertrophy (37,39).  Additionally, in vivo studies 
have shown that RUNX2 regulates the expression of two different splice variants of the 
transcription factor ETS related gene (ERG) whose expression is important for regulating the 
development of chondrocytes into permanent or transient cartilage (38,40-42).  
 
Cartilage injuries and treatment 
Cartilage injuries 
Because of the highly specialised nature of articular cartilage, the integrity of the ECM is 
crucial for the health and function of the tissue. Once injured, the articular cartilage has a 
poor healing capacity due to the lack of vascularisation and the fact that it is almost 
impossible for the cells to migrate to injured areas because of the high density of the ECM. 
This feature makes damage and diseases of the articular cartilage one of the leading causes of 
chronic disability in developed countries (43). Most articular cartilage injuries are a result of 
direct mechanical trauma to the cartilage or progressive degeneration as seen in osteoarthritis 
(OA) (44).  
It has been documented that 60-65% of patients undergoing knee arthroscopy have 
cartilage lesions (45-48) and that sports activity is the most commonly associated event (48). 
Focal cartilage lesions not only give rise to pain, but such lesions will enlarge with time and 
in many cases contribute to the development of OA (44). OA is a multifactorial disease of the 
whole joint that leads to degradation of the articular cartilage. The exact causes of OA are not 
known, but there are many factors, such as age, blunt trauma, obesity, inflammation, diabetes, 
genetics and joint pathologies, associated with the development of OA (44). When the articular 
cartilage in the joint is degraded, the subchondral bone will be exposed and the bone surfaces 
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will rub against each other. This results in inflammation, pain, swelling and stiffness of the 
joint. In addition to impairing the quality of life for millions of people, OA is also an 
economic burden for society. In 2003, the total cost of arthritis and other rheumatic 
conditions in the United States was estimated to be $128 billion (49). 
 
Treatment 
The ultimate goal of cartilage repair is to produce a tissue that has identical properties to 
native cartilage and that integrates with the surrounding tissue of the lesion. Many surgical 
techniques have been developed, but so far none of the techniques fulfils these requirements 
(44,50). The repair tissue often consists of fibrocartilage, bone, hyaline-like tissue or a mixture 
of these tissues (51,52). Although such treatments do not result in a perfect repair tissue, many 
patients experience improved functionality and relief of pain. This is the main reason for 
performing these treatments today. Autologous chondrocyte implantation (ACI), or 
autologous chondrocyte transplantation, is the most widely used cell-based procedure for 
cartilage repair. Because ACI is the relevant treatment procedure for this thesis, a description 
will be given below. For a detailed discussion of the other therapeutic strategies, the following 
review and book are recommended (44,50). 
 
Autologous chondrocyte implantation 
In 1994, Brittberg et al., published the first paper on cartilage treatment using ACI (53). Since 
then, more than 35,000 patients have been treated using this procedure (44).  Figure 4 shows 
the classical ACI technique.  
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Figure 4. Autologous chondrocyte implantation procedure. The figure is explained in the text (from 
Brittberg et al., 1994)(53). 
 
A small cartilage biopsy from a non-weight bearing area of the knee (such as the superior and 
the lateral intercondylar notch or from the edges of the lateral or medial femoral condyles) is 
harvested and enzyme-treated to release the cells from the ECM. The cells are then expanded 
(cultured) to obtain a sufficient number to be used for implantation. The cells are then injected 
into the lesion under a periosteal flap (53). This process represents the first generation of ACI. 
However, the periosteal flap may lead to hypertrophy and periosteal delamination. To 
overcome these problems, researchers have developed a second generation of ACI where the 
periosteal flap has been replaced by a collagenous membrane (collagen-covered ACI - CACI). 
CACI results in less hypertrophy compared with the first-generation ACI. Otherwise, the 
clinical improvement is the same (54). To further improve the ACI procedure, a third 
generation of ACI has been developed. This procedure involves seeding cultured ACs onto a 
collagen membrane (matrix-induced ACI – MACI) or the use of cultured ACs within other 
three-dimensional scaffolds (such as Hyalograft C, Novocart 3D, Cartipatch and BioSeed-C) 
(54). The third-generation ACI has been shown to yield good or excellent results in clinical 
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trials, but there is no difference between CACI and MACI when comparing the clinical, 
arthroscopic and histological outcomes (55). 
As shown in Figure 4, ACI requires ex vivo monolayer expansion of the patient’s own 
ACs. Monolayer expansion of the cells leads to dedifferentiation. This means that the cells 
lose their phenotype, and synthesis of the hyaline cartilage-specific proteins, such as type II 
collagen and aggrecan, is replaced by synthesis of type I collagen and versican, respectively 
(56,57). Type I collagen and versican are components of fibrocartilage.  Therefore, 
transplantation of dedifferentiated ACs results in a repair tissue consisting of fibrocartilage or 
a mix of fibrocartilage and hyaline cartilage (52). Although this repair tissue improves 
functionality and alleviates symptoms, it does not have the mechanical and osmotic properties 
of hyaline cartilage and it will eventually degrade (44). This is a major limitation for the use of 
ACs in ACI. The reason for dedifferentiation is not fully known, but it is thought to involve 
the actin cytoskeleton and the spreading or flattening of the cells when they attach to the 
culture surface during monolayer expansion (58,59). Understanding the mechanism behind 
dedifferentiation may lead to new strategies for ex vivo expansion in which the ACs do not 
dedifferentiate, thus improving the quality of the repair tissue and the clinical outcome of ACI. 
Other factors, such as age, ligament stability, meniscus damage and the size of the defect also 
affect the quality of the repair tissue (44). Another limitation of ACI is the need for two 
surgical interventions, one to harvest the biopsy and one to transplant the cultured cells 
(Figure 4). Harvesting the biopsy also leads to donor site morbidity, but it does not seem to 
create problems during ACI in the knee. However, most studies using MRI do not mention 
donor-site morbidity and there are no published data on the anatomy or histology of the 
donor-site (60). 
Introducing another cell source may not only improve the clinical outcome of ACI, but 
it will also avoid the need to harvest a biopsy from the knee and prevent potential problems 
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related to donor-site morbidity. Stem cells are an alternative cell source for cartilage repair. In 
the next section, I will describe some of the basic biology of stem cells and then focus on 
mesenchymal stem cells (MSCs) as candidates for cartilage repair. 
 
Stem cells 
Stem cell research holds great promise for regenerative medicine and tissue engineering in 
medical research, including cartilage repair. A stem cell, by definition, is an undifferentiated 
(or unspecialised) cell that can produce both new stem cells (self-renewal) and cells that 
commit to differentiation (specialisation) (Figure 5). The daughter cells committed to 
differentiation first become precursor cells. These can divide symmetrically to form more 
precursor cells, or differentiate further to become tissue specific, end-differentiated cells (61). 
 
 
 
 
 
Figure 5. Definition of a stem cell. See text for explanation (from Raff, 2003)(61). 
 
Stem cell differentiation is the process where an undifferentiated stem cell changes its features 
to become a more specialised cell, such as a neuron, chondrocyte or a muscle cell. In vivo, 
stem cells usually remain undifferentiated and in a slowly proliferating state until they receive 
a signal that causes them to commit to differentiate (62). The differentiation signal triggers the 
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altered expression of genes involved in the cell cycle and tissue development. Depending on 
the signal, some cells will divide and produce identical daughter cells to maintain the stem 
cell pool, while others will divide to generate differentiated cells.  
 
Classification of stem cells 
Some stem cells can produce a variety of differentiated cells (63), while other stem cells can 
produce only a few or one type of differentiated cells (64). The differentiation potential largely 
depends on where in the body or from which stage in development the stem cells arise. Stem 
cell researchers typically draw a distinction between embryonic stem cells and adult stem 
cells.  
 
Embryonic stem cells 
After fertilisation, the egg is referred to as a zygote. The zygote is totipotent, meaning that it 
is capable of giving rise to all the cell types that are necessary to form an individual, including 
those that do not form part of the embryo, such as the cells of the placenta and umbilical cord. 
Between four to six days after fertilisation, the zygote has developed into a blastocyst (65). The 
blastocyst contains two layers of cells, an outer layer called the trophectoderm and an inner 
layer called the inner cell mass (ICM). The cells of the trophectoderm are involved in 
implantation and the formation of the placenta, while the ICM develops into the three germs 
layers (ectoderm, endoderm, and mesoderm) that eventually give rise to all the cells and 
organs in the adult body. Embryonic stem cells (ESCs) are established by removing the ICM 
from the blastocyst and growing the cells in vitro (Figure 6) (63).  
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Figure 6. Derivation of embryonic stem cells (modified from Yabut et al., 2011)(66). 
 
ESCs are pluripotent, meaning that they are undifferentiated cells that have the potential to 
give rise to all the different cells in the adult body. Pluripotency can be demonstrated by 
injecting the cells under the skin of immune-deficient mice where they will form teratomas 
(noncancerous tumours) consisting of cells of all three germ layers (67). Alternatively, the cells 
can be established in three-dimensional aggregates called embryoid bodies that also give rise 
to cells of the three germ layers (68). Studies of ESCs show that relatively few genes are 
required for self-renewal. The expression of OCT4, SOX2, KLF4 and cMYC all decrease 
during ESC differentiation (69-73), and in 2006, Yamanaka and colleagues showed that forced 
expression of these four genes was sufficient to re-programme differentiated cells and turn 
them into self-renewing ESC-like cells (74). These cells are called induced pluripotent stem 
cells (iPSCs), and with John Gurdon Yamanaka won the Nobel Prize in Physiology and 
Medicine 2012 for this excellent work. 
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Adult stem cells 
Stem cells are present in most, if not all, organs in the body, and they are referred to as adult 
stem cells (ASCs). An important role of ASCs is to maintain tissue homeostasis and repair by 
replacing apoptotic cells as a part of normal tissue/cell turnover and by replacing damaged 
cells following injury. In the tissues, the ASCs have their own specialised environment called 
the stem cell niche (62,75). The adult stem cell niche is poorly defined, but it consists of all the 
components of the microenvironment in which the ASCs reside, such as other cells, ECM 
molecules, oxygen tension and factors secreted by cells. Both extrinsic signals from the niche 
and intrinsic signals arising within the stem cells control the balance between self-renewal and 
differentiation. In this way, the ASCs maintain a pool of stem cells (self-renewal) and serve as 
a reservoir to replace cells (differentiation) when needed. ASCs have a more restricted 
differentiation potential than ESCs. Typically, ASCs differentiate into cell types that 
correspond to the organ or tissue from which they originated. This restricted differentiation 
potential is often referred to as multipotency. It has been reported that ASCs can also 
differentiate into lineages that are different from their organ/tissue of origin (76,77).  
 
Mesenchymal stem cells 
MSCs, also called multipotent mesenchymal stromal cells, are multipotent cells that can be 
isolated from many tissues including adipose tissue (78,79), bone marrow (80), teeth (81), 
periosteum (82), synovial membrane (83), placenta (84), umbilical cord blood and skeletal muscle 
(85). MSCs were first described by Friedenstein and colleagues more than four decades ago (80). 
Friedenstein isolated cells from bone marrow that adhered to plastic surfaces and formed 
fibroblast-like colonies (colony forming unit-fibroblasts – CFU-U) when plated at a low 
density. In vivo transplantation demonstrated that a single cell could give rise to bone, 
26 
 
cartilage, adipose and fibrous tissue (80,86,87). MSCs consist of a heterogeneous group of cells 
with varying proliferation and differentiation potentials (88,89). Studies have shown that these 
cells can be cultured for many passages in vitro and that they can differentiate into several 
mesodermal cell types, such as osteocytes, adipocytes, chondrocytes and myoblasts (Figure 7) 
(90-92).  
 
 
 
 
 
 
 
Figure 7. Differentiation potential of MSCs (from Risbud et al., 2002)(92). 
 
Characterisation of MSCs 
Because laboratories around the world have used different protocols for the isolation and 
expansion, as well as different approaches for characterisation of these cells, the 
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular 
Therapy (ISCT) has proposed three criteria to define human MSCs (93). First, the cells must 
adhere to plastic surfaces.  Second, MSCs should express certain cell surface markers, and 
95% or more of the cell population should express CD105 (endoglin), CD73 
(ectonucleotidase) and CD90 (thy-1). Because MSCs are isolated from tissues containing 
many different cells, the MSC cultures may be contaminated by other cell types, such as 
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hematopoietic cells. Therefore, it is recommended that cultured MSCs do not express (less 
than 2%) the hematopoietic stem cell marker CD34, the hematopoietic marker CD45, one of 
the two macrophage markers CD14 or CD11b and one of the two B-cell markers CD79α or 
CD19. MSCs should not express HLA-DR, but this molecule can be induced by stimulating 
the cells with interferon-γ (94). The third criterion requires that the cells must be able to 
differentiate into osteocytes, adipocytes and chondrocytes in vitro. 
 
In vivo localisation of MSCs 
MSCs can be isolated from many tissues, but the exact origin and in vivo niche of MSCs are 
not fully known. However, MSCs in the bone marrow surround small blood vessels (sinusoids) 
and have a very important role in the niche of haematopoietic stem cells (HSCs) (95). MSCs 
express HSC regulatory molecules, such as CXCL12, which facilitates homing of 
hematopoietic progenitors and hematopoiesis (96). Transplantation of MSCs has also shown 
that these cells can organise the hematopoietic microenvironment (97)). Recently, MSCs have 
been shown to have a perivascular location in several tissues, suggesting that MSCs and 
pericytes (cells that wrap around endothelial cells in capillaries) are the same cells (98-100). If 
MSCs are pericytes, it would explain why MSCs are found in many tissues and it would also 
allow MSCs to easily access most tissues/organs for repair/tissue homeostasis. Another 
possibility is that stem cells from various tissues acquire MSC characteristics when 
established in vitro (100). In vivo studies have shown that MSCs can migrate to various organs 
in the body after transplantation (101,102), and Rochefort et al. demonstrated mobilisation of 
MSCs into the peripheral blood when rats were exposed to hypoxia (103).  In contrast to the 
MSC/pericyte theory, this finding suggests that MSCs are located in one or a few organs and 
that they can enter the circulation and migrate to other tissues after stimulation. However, the 
difficulty of isolating MSCs from the peripheral blood argues against this theory. 
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MSC self-renewal  
Understanding signalling pathways and the factors controlling self-renewal and differentiation 
of MSCs is important for the clinical use of these cells. Clonal studies of MSCs derived from 
human umbilical cord demonstrated a hierarchical schema for self-renewal and differentiation 
(104). The authors observed no difference in CFU-U formation between parent cells and 
daughter cells (clones), suggesting self-renewal and maintenance of the stem cell pool. 
Further support for self-renewal was based on the fact that daughter clones maintained the 
ability to differentiate after 40 cell doublings. There has been a debate regarding whether 
MSCs are able to self-renew, and there is a lack of robust and reproducible methods for 
assaying self-renewal in these cells. However, in vivo studies have shown that colony forming 
CD146+ MSCs are capable of organising a hematopoietic environment (heterotopic bone 
marrow) in mice and that the same CD146+ cell population can be isolated from the 
heterotopic bone marrow and subsequently passaged and assayed for colony formation (97). 
Another group demonstrated that Nestin+ MSCs were able to self-renew and give rise to 
heterotopic bone marrow in serial transplantations (105). Although these studies provide some 
evidence for the self-renewal of MSCs, there are no standardised or robust assays to confirm 
the self-renewal of MSCs. The signalling pathways regulating self-renewal in MSCs are not 
well understood. As already mentioned, OCT4, SOX2, KLF4 and CMYC are important for 
self-renewal of ESCs. Human bone marrow MSCs do not express SOX2, but they do express 
low levels of OCT4 and NANOG (another important “pluripotent gene”) and moderate/high 
levels of CMYC and KLF4 (Master thesis: Tommy Aleksander Karlsen, 2007, University of 
Oslo, Norway). The roles of these genes in MSCs are unclear, but knockdown of OCT4 and 
NANOG inhibited proliferation and differentiation of MSCs, suggesting that these genes have 
a role in self-renewal (106). Leukemia inhibitory factor (LIF) maintains the undifferentiated 
state of MSCs (107)). The mechanism is not known, but in mouse ESCs LIF controls self-
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renewal through a CMYC-dependent mechanism (73). Fibroblast growth factor (FGF) 2 
increases the lifespan and differentiation capability of MSCs from a range of species when 
cultured as a monolayer, suggesting that FGFs have an important role in the self-renewal of 
MSCs (108). Other cytokines and signalling pathways, including WNT (Wingless) (109), the 
WNT inhibitor Dickkopf-1 (110), tumour necrosis factor-α, platelet-derived growth factor 
receptor β (111), polycomb chromatin-associated proteins (112), and Notch (113) all have roles in 
the determination of cell fate in MSCs, but the mechanisms are not fully understood.  
  
Chondrogenic differentiation 
As shown in Figure 7, MSCs can differentiate into several lineages, including chondrocytes. 
For several years, researchers have used different growth factors and three-dimensional 
cultures to induce chondrogenesis of MSCs in vitro. Some of the main strategies of 
chondrogenic differentiation will be described here. 
 
In vitro chondrogenesis using pellet cultures 
The pellet culture is a simple procedure where the cells are centrifuged and cultured as a 
pellet in the bottom of a tube. This is analogous to the condensation phase in vivo, where cell-
cell contact is established. The pellet culture has been used to study many aspects of 
chondrogenesis, including condensation, hypertrophy and the influence of oxygen 
concentration and mechanical hydrostatic pressure (114-118). The pellet culture was first 
described in 1960 in an attempt to maintain the differentiated state of chicken embryonic ACs 
in culture (56). Seven years later, the pellet culture was applied to human ACs (119). Since the 
studies by Friedenstein in the 1970s, it was clear that MSCs were capable of differentiating 
into chondrocytes in vivo, but it was not until 1998 that in vitro chondrogenesis of MSCs was 
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demonstrated (120). In contrast to ACs, the MSCs did not form aggregates unless a defined 
culture medium containing TGF-β and/or dexamethasone was used. Sekiya et al. improved 
chondrogenesis by adding BMPs to the chondrogenic induction medium (121,122). Today, 
several combinations of growth factors and hormones are used in the chondrogenic induction 
medium. The most commonly used are TGF-β, BMPs and dexamethasone (121-123), but in some 
protocols, FGF2, IGF-I and/or PTHrP are also used (124,125). TGF-β and BMPs belong to the 
TGF-β superfamily and have a broad range of biological activities, including proliferation, 
differentiation and apoptosis (4). In mammals, there are three different TGF-β proteins (TGF-
β1-3), and they elicit their biological functions by binding to TGF-β-receptors, resulting in 
phosphorylation of Smad proteins. The phosphorylated Smad proteins then translocate to the 
nucleus where they regulate gene expression (12). The BMPs are a large group of proteins (at 
least 20) that act through the same receptors as TGF-β but engage another set of Smad 
proteins (12). For a more comprehensive description of TGF-β, BMPs and other growth factors, 
as well as their role in chondrogenesis/cartilage, the following book is recommended (4). 
Micromass culture is another method that is very similar to the pellet culture method. 
Instead of making pellets by centrifugation, the cells are suspended at a very high cell density 
in medium and allowed to self-assemble into small aggregates (126,127). 
 
In vitro chondrogenesis using three-dimensional scaffolds 
Pellet cultures often contain necrotic cells at the centre of the pellet, possibly as a result of 
inadequate diffusion of nutrients (128). The pellets also have a very small size (~200,000 
cells/pellet), making it difficult to obtain a large number of differentiated cells. Thus, the 
clinical use of pellet cultures has limitations, and this method is therefore not used for these 
purposes (129). As described in the section “Autologous chondrocyte implantation” (page 19), 
cultured chondrocytes can be seeded or embedded in three-dimensional scaffolds before 
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implantation. This principle has been applied for in vitro chondrogenesis of both MSCs and 
ACs.  
There are various types of three-dimensional scaffolds, and new scaffolds are 
constantly being developed. Scaffolds can broadly be divided into three groups (50,130). The 
first group consists of protein-based polymers such as collagen, fibrin and gelatin. The second 
group corresponds to carbohydrate-based polymers, such as alginate, hyaluronic acid, agarose 
and chitosan. Artificial, or synthetic, polymers constitute the third group and include scaffolds 
made of materials such as carbon fibres, Dacron, polyester-urethane and hydroxyapatite. It is 
also possible to make scaffolds consisting of several types of materials or to incorporate 
molecules for attachment and/or cell signalling purposes. In general, scaffolds should support 
cell viability and proliferation, be biocompatible, biodegradable, provide sufficient structural 
and mechanical support, provide a uniform distribution of cells and contain large enough 
pores to allow the diffusion of nutrients and the removal of waste products. For tissue 
engineering purposes, the scaffold material should also allow for integration of the newly 
synthesised tissue with the adjacent tissue (130). A large number of scaffolds have been used to 
support chondrogenesis. Still, there are no scaffolds (or other methods) available today that 
promote the formation of perfect articular cartilage in vitro or in vivo, reflecting the complex 
nature of this tissue (131).  The goal of combining cells and scaffolds is to provide an 
environment that mimics the effect of the native environment surrounding the cells in vivo. 
Reconstructing the in vivo environment of ACs within a scaffold is a difficult, if not 
impossible, task. However, studies have shown that both MSCs and dedifferentiated ACs are 
capable of surviving and differentiating toward the chondrogenic lineage in a wide range of 
scaffolds (130). Hopefully, mimicking some aspects of the native environment will be sufficient 
to support the formation of articular cartilage with properties comparable to the native tissue. 
This will eventually improve the clinical outcome for patients in the future.  
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Immunomodulatory effects of MSCs 
MSCs are regarded as immune privileged cells based on observations that allogeneic MSCs 
avoid immune recognition (132). MSCs have also been used for treatment of graft-versus-host 
disease in humans with promising results (133,134).  In vitro studies show that MSCs have the 
capability to suppress the function of T-cells, B-cells, natural killer cells, inhibit maturation of 
dendritic cells and regulate activation of macrophages (135,136). MSCs exert their 
immunosuppressive function by secreting soluble factors, such as indoleamine 2,3-
dioxygenase, nitric oxide and prostaglandin E2 and through direct cell-cell contact (135,136). 
Ren et al. demonstrated for example that an increased expression of intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlated with the 
immunosuppressive capacity of MSCs, while blocking or deleting these adhesion molecules 
inhibited immunosuppression (137).  
 
microRNAs 
MicroRNAs (miRNAs) are small double-stranded RNA molecules that regulate gene 
expression by targeting complementary nucleic acid sequences. miRNAs are transcribed as 
large transcripts called primary miRNA (pri-miRNA) (Figure 8). In the nucleus, pri-miRNAs 
are recognised and processed by the Drosha microprocessor complex (138). The resulting 
product is called precursor miRNA (pre-miRNA) and contains a two-nucleotide overhang at 
its 3’-end. The Exportin complex then transports the pre-miRNAs into the cytoplasm where 
Dicer cleaves the pre-miRNA into mature double-stranded miRNA molecules approximately 
21-23 nucleotides in length (139). One or both of the strands is incorporated into the RISC 
complex where it will interact with complementary mRNA molecules by base pairing, 
resulting in either degradation of the mRNA or translational repression (140,141). The two 
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strands of the pre-miRNA may give rise to two mature miRNAs. These are given the suffix 
“5p” (from the 5’ arm) or “3p” (from the 3’arm). The suffix “5p” or “3p” is not always used 
in the literature. In this thesis, the lack of “5p” and “3p” refers to the mature miRNA from the 
5’arm (5p).  For further information on the nomenclature of miRNAs, please visit the 
miRbase database (http://www.mirbase.org/). 
 
 
 
 
 
 
 
 
 
Figure 8. miRNA biogenesis. The figure is explained in the text (from He et al., 2004)(142). 
 
Recently, miRNAs have also been shown to enhance gene expression. In some 
situations, this may occur through activation rather than repression of translation (143,144). In 
other situations, miRNAs may bind to promoters with complementary sequences to induce or 
repress transcription (145,146). One miRNA may have more than one hundred different mRNA 
molecules as targets (147), and experiments have demonstrated that a single miRNA can affect 
the expression of hundreds of proteins, directly or indirectly (148). Today, more than 2000 
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miRNAs have been discovered in humans (www.miRbase.org), and estimations suggest that 
60% of our genes are regulated by microRNAs (149). Thus, miRNAs are likely to be involved 
in most biological processes.  
 
Role of miRNAs in cartilage, chondrogenesis and osteoarthritis  
MiRNAs are necessary for the development of normal cartilage, as mice with chondrocytes 
lacking the Dicer gene exhibit severe skeletal defects (150). Studies in mouse and zebrafish 
embryos have identified miR-140 as a cartilage-specific miRNA (151,152).  MiR-140 is located 
in an intron in the WWP2 gene and is induced by SOX9 (153,154). Recently, it was demonstrated 
that SOX5/6 increases the transcription of miR-140 by boosting dimerisation and DNA 
binding of SOX9 (155).  The importance of miR-140 in cartilage development has been shown 
in in vivo studies. Miyaki et al. showed that miR-140-deficient mice have an OA-like 
pathology and a shorter skeleton compared to wild-type mice, while transgenic mice 
overexpressing miR-140 were resistant to antigen-induced arthritis (156). It was also 
demonstrated that miR-140 provided resistance to proteoglycan and type II collagen loss and 
that ADAMTS5 (a matrix-degrading protease) was a direct target of miR-140, partially 
explaining the protective role of miR-140 against OA progression.  In another in vivo study, 
Nakamura et al. showed that the loss of miR-140 impaired endochondral bone formation by 
accelerating hypertrophic differentiation. Further, it was demonstrated that miR-140 could 
modulate BMP signalling by targeting DNPEP (157). In micromass cultures miR-140 regulates 
proliferation by targeting the transcription factor SP1 (153). In vivo miR-140 is expressed in 
proliferating chondrocytes supporting the regulatory effect of miR-140 on proliferation (156). 
PDGFRA is another target of miR-140 and is important in palatogenesis in zebrafish (158), 
while the TGF-β superfamily modulator SMAD3 has been shown to be a target in C3H10T1/2 
cells (159). Other validated targets of miR-140 are BMP2, CXCL12 and HDAC4 (151,160,161).   
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 In addition to miR-140, other miRNA may also have important roles during cartilage 
development. SOX9 has been verified as a target of miR-145 in two studies (162,163). In bovine 
articular cartilage, miR-222 plays a role in mechanotransduction (164), while miR-221 has been 
reported to be a negative regulator of chondrogenesis in chick limb mesenchymal cells (165). 
Overexpression of miR-675 positively regulates type II collagen expression possibly via a 
SOX9-dependent mechanism (166). MiR-199a inhibits early BMP2-induced chondrogenesis in 
C3H10T1/2 cells by targeting SMAD1 (167). In rats, several miRNAs were shown to be 
upregulated during the development of articular cartilage. These include miR-25, miR-26a, 
miR-140, miR-150, miR-181a and miR-210, while miR-1 was downregulated (168). In another 
study miR-1 was found to be repressed during hypertrophic differentiation and to inhibit the 
expression of aggrecan (169). MiR-365 is highly expressed in hypertrophic chondrocytes and 
stimulates type X collagen (170). Besides miR-140, the dysregulation of several miRNAs is 
also associated with OA, including the suppression of miR-25, miR-26a, miR-27a, miR-27b, 
miR-29a, miR-210, miR-337, miR-373 and the upregulation of miR-9, miR-16, miR-22, miR-
23b, miR-30b, miR-34a, miR-34b, miR-103, miR-223, miR-377, miR-455, miR-483 and 
miR-509 (171-173). Mir-146a may also be involved in OA, but it seems to be expressed 
differently depending on the developmental stage of OA (174).  
 
Potential clinical applications of miRNAs  
Endogenous miRNAs regulate many genes, and it is possible for one miRNA to regulate 
many genes belonging to the same biological pathway. One mRNA may also be targeted by 
several miRNAs (175-177). Thus, it is not unexpected that the dysregulation of miRNAs is 
associated with several diseases, including OA (156,173). In animal models, synthetic miRNA 
mimics and inhibitors have demonstrated promising results. Administration of a let-7b mimic 
reduced tumour formation in mice, while treatment of hepatitis C virus (HCV) infected 
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chimpanzees with a miR-122 inhibitor (HCV replication is miR-122-dependent) reduced 
HCV viremia and improved liver pathology compared to control animals (178,179). Because of 
their important role in gene regulation and their promising results in animal studies, 
manipulation of endogenous miRNAs has attracted the attention of the biomedical research 
community, and in 2008, Santaris Parma A/S commenced the first human clinical trial for an 
miRNA-targeted drug (a miR-122 inhibitor) (www.santaris.com). In 2010, the study was 
advanced to a phase 2a clinical trial, and the results were announced in November 2011. So 
far, the drug appears to be both effective and safe for treating HCV patients (180). 
One advantage of the use of small synthetic miRNA mimics or inhibitors in therapy is 
that they do not integrate into the genome and therefore offer greater safety than gene therapy 
utilising DNA plasmids. Compared to large gene constructs, these small RNA molecules (21-
23 nucleotides) are easier to introduce into cells and because they function in the cytoplasm, 
they do not need to enter the nucleus, thus avoiding the use of complex delivery systems. 
Another major advantage of manipulating miRNAs is that several target genes belonging to 
the same biological process can be affected by manipulating only a single miRNA. For 
example, a tumour-suppressor miRNA may target both anti-apoptotic genes and genes 
involved in angiogenesis and the cell cycle. Such tumour-suppressor miRNAs are often 
downregulated in several types of cancers (178,181). By restoring endogenous miRNAs with 
synthetic mimics, multiple cancer-genes can be targeted at the same time. This principle can 
also be used for targeting miRNAs involved in chondrogenesis and the development of OA. 
To use miRNA mimics or inhibitors in therapy, it is necessary to understand the 
biological role of the miRNA to be manipulated. Thus, many in vitro and in vivo experiments 
have to be performed prior to clinical trials. The usefulness of these studies depends on the 
efficiency of the miRNA mimic/inhibitor for inducing specific changes in target genes and 
their downstream mediators. Different delivery methods are used for introducing 
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mimics/inhibitors to cells. One commonly used method is the use of lipid-based transfection 
reagents (liposomes). These reagents are made to mimic the properties of biological lipids to 
ensure fusion with cell membranes and delivery of the nucleic acids into the cell either via the 
endosomal pathway or by direct delivery into the cytoplasm (182,183). Both in vivo and in vitro 
experiments have shown that lipid-based transfection reagents activate the innate immune 
system (184-186). RNA molecules may also activate the innate immune system. This occurs by 
recognizing the RNA by RNA receptors located either in the endosomes or in the cytoplasm 
(187). Unintended activation of immune responses by liposomes and/or RNAs can potentially 
mask or change the cellular response to the synthetic miRNA mimic/inhibitor used and can 
confuse the interpretation of results. Furthermore, these effects could potentially harm patients. 
Understanding the molecular mechanisms behind these effects and how to avoid them are 
therefore important if these reagents are to be employed in clinical trials.  However, in certain 
situations, an immune response may actually be beneficial. This scenario is described in the 
General discussion section of this thesis.  
 
Cellular receptors for foreign RNA  
The mechanisms behind liposome-induced immune response are largely unknown. However, 
toll-like receptor 4 (TLR4) induces the secretion of interleukins after liposome stimulation 
(188). The liposome induced immune response has also been shown to depend on STING (an 
ER transmembrane protein) (184). Certain lipid receptors in the cell membrane are known to 
induce upregulation of immune genes and may also be involved (189,190).   
Regarding transfection and immune responses (also referred to here as immunological 
off-target effects), much more is known about pattern recognition receptors (PRRs) and their 
role in sensing nucleic acids. PRRs can be divided into membrane-bound PRRs and 
cytoplasmic PRRs. PRRs are used by the innate immune system to recognise structures called 
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pathogen-associated molecular patterns (PAMPs) that are shared among related microbes, 
such as single and double-stranded RNA from viruses and lipopolysaccharides found in the 
outer membrane of Gram-negative bacteria (191). After detection of PAMPs, PRRs are 
activated and initiate an immune response as a defence mechanism against invading microbes 
(191). There are many PRRs, and only the PRRs that sense RNA will be introduced here. 
 
Toll-like receptors 
TLRs are membrane-bound proteins found at the cell surface and in endosomes. All TLRs 
have an extracellular domain containing leucine-rich repeats that mediates the detection of 
PAMPs and an intracellular signalling domain called Toll-interleukin (IL-1) receptor (TIR). 
In humans, ten TLRs (TLR1-10) have been identified in which TLR3, 7, 8 and 9 are located 
in the membranes of endosomes where they interact with microbial nucleic acids. The other 
TLRs are situated in the plasma membrane and recognise PAMPs other than nucleic acids, 
such as flagellin, peptidoglycan and lipopolysaccharide (191). Once activated by PAMPs, the 
TLRs recruit adaptor proteins that in turn initiate a signalling cascade resulting in the 
production of antiviral factors that are important in the first line of defence against viral 
infections (191).  
The TLRs that respond to RNA are TLR3, TLR7 and TLR8, and they are located in 
the membranes of endosomes. While TLR3 has double-stranded RNA (dsRNA) as a ligand 
and signals through the adaptor protein TIR-domain-containing adapter-inducing interferon-β 
(TRIF), TLR7/8 detects single-stranded RNA (ssRNA) and uses myeloid differentiation 
primary response 88 (MYD88) as an adaptor protein (Figure 9) (187). Interestingly, TLR7/8 
were also shown to be activated by dsRNA (siRNA duplexes) (191,192). From the adaptor 
proteins, the signalling cascade may proceed through different pathways depending on the cell 
type and which TLR receptor is activated. At the end, all of the TLRs engage transcription 
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factors involved in the NF-κB and IRF pathways, leading to the expression of antiviral factors 
such as proinflammatory cytokines and type I interferons to inhibit the replication and 
spreading of viruses (Figure 9) (191). 
 
 
 
 
 
 
 
 
Figure 9. Cellular sensors, adaptor molecules and cytokines involved in innate immune responses to 
foreign RNA (from Olejniczak et al., 2010)(187). 
 
The retinoic acid-inducible gene-I-like receptors 
Unlike TLRs, which are membrane-bound PRRs, the retinoic acid-inducible gene-I-like 
receptors (RLRs) are cytoplasmic PRRs. The RLRs constitute three members of the DExH/D-
box RNA helicase family and include retinoic acid-inducible gene-I (RIG-I), melanoma 
associated gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) (193)). RLRs 
also function as sensors of viral RNA. RIG-I binds preferentially to short dsRNA, while 
MDA5 binds to long dsRNA (1-10 kb in length) (194,195). The function of LGP2 in virus 
recognition is controversial, and it has been reported to act as both a negative and positive 
regulator of RIG-I (196,197). 
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RIG-I, the dsRNA receptor investigated in paper III, contains two N-terminal caspase-
recruiting domain (CARD)-like domains, a central helicase domain and a C-terminal 
regulatory domain (RD) (Figure 10) (198). The CARD domains interact with the downstream 
mediator mitochondrial antiviral signalling (MAVS, also known as IPS-1), leading to 
activation of the same transcription factors involved in TLR signalling (NF-κB and the IRF 
pathways) and the expression of proinflammatory cytokines and type I interferons (see Figure 
9) to ensure that the infecting virus is destroyed.  
 
 
 
Figure 10. Structure of RIG-I. See text for details (from Baum et al., 2010)(198). 
 
The helicase domain is involved in the recognition and unwinding of the foreign RNA, and it 
also appears to cooperate with the RD domain to optimise the binding to the RNA (199-201). In 
non-infected cells, RIG-I has been suggested to be folded in such a way that the RD domain 
interacts with the CARD domains and prevents them from signalling through MAVS (202). 
During virus infection, a conformational change results in displacement of the repressing RD 
domain, thereby enabling interaction of CARDS with MAVS and subsequent signalling. RIG-
I activity is also negatively and positively regulated by phosphorylation and ubiquitination, 
respectively (203,204). In addition, RIG-I is upregulated, though not activated, by cytokines, 
such as type I interferons, IL-1β and TNF-α (193).    
Generally, short dsRNAs rich in GU or polyU motifs have been shown to be more 
likely to induce immune responses via RIG-I (205). In addition, RIG-I binds short, blunt-ended 
uncapped dsRNA, preferably with 5’triphosphate (ppp) groups, though RIG-I has also been 
 
41 
 
shown to bind dsRNA without 5’ppp and ssRNA containing 5’ppp (200,206-208). The lack of a 
cap is typical of viral sequences, and this feature allows RIG-I to discriminate between self 
and viral dsRNAs (209). dsRNA containing overhangs, such as endogenous miRNAs, may 
inhibit immune gene induction through RIG-I, thus introducing another mechanism by which 
the cell can discriminate between self and non-self dsRNAs (200). However, blunt ends are not 
always a requirement for RIG-I activation, as shown in paper III, where both blunt ends and 
overhangs stimulated an immune response via RIG-I. The results presented in paper III also 
show that synthetic miR-145 induced an immune response in MSCs via RIG-I when it was 
delivered by liposomes, but this was not the case when smiR-145 was delivered directly into 
the cytoplasm by electroporation, suggesting that RIG-I depends on liposome delivery in 
certain situations (paper III). Thus, the choice of delivery vehicle is crucial for avoiding 
immunological off-target effects that can complicate the interpretation of results from in vitro 
and in vivo transfection experiments. 
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Aims of the study 
The overall aim of this thesis was to investigate the role of miRNAs during dedifferentiation 
and chondrogenic differentiation of ACs and MSCs, respectively.  
Thus, the specific aims in this thesis were 
- To investigate the global miRNA changes during dedifferentiation of ACs to identify 
possible miRNAs important for cartilage development and repair. 
 
- To compare the global miRNA expression profile of uncultured ACs with that of 
chondrogenically differentiated MSCs. 
 
- To investigate the role of miRNAs that showed a reciprocal relationship during 
dedifferentiation/differentiation and to reveal their possible targets. 
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Summary of results 
Paper I 
In this study, we isolated human primary uncultured ACs. When these cells were allowed to 
proliferate within their own ECM, they began to produce hyaline ECM molecules similar to 
embryological chondroblasts. Upon continued culture, these cells spread onto the plastic 
surface and dedifferentiated. Thus, the ACs went through three stages during 28 days of in 
vitro culture: (1) primary, uncultured non-proliferating ACs (day 0); (2) the chondroblast-like 
stage (day 7–14); and (3) the dedifferentiation stage at the end of the culture. The three cell 
populations were investigated with respect to their expression of a large number of genes, 
miRNAs and proteins related to chondrogenesis. Gene expression was quantified by RT-
qPCR, miRNAs were evaluated by miRNA arrays, and protein synthesis was investigated by 
extra- and intracellular flow cytometry. The three stages were characterised by the differential 
expression of genes encoding many of the collagens and transcription factors related to 
articular cartilage, such as COL2A1, COL9A1, and COL11A1, SOX9, SOX5, and SOX6. The 
miRNA profiling revealed four clusters of expression patterns. One cluster consisted of miR-
451, which was only upregulated in stage 1. Four miRNAs, including miR-140-3p, were 
upregulated in COL2A1 producing cells (stage 1 and 2). MiR-140-5p showed the same 
expression pattern and was significant with p<0.05. Another cluster consisted of five miRNAs, 
including miR-221 and miR- 222, that were upregulated in proliferating cells (stage 2 and 3). 
The last cluster consisted of 11 miRNAs, including miR-143 and miR-145, and was 
upregulated only in dedifferentiated cells (stage 3). Several of these miRNAs were predicted 
to regulate cartilage-related genes, such as COL2A1, SOX9, SOX5 and SOX6. Because adult 
chondroblast-like cells (stage 2) still express type II collagen and other important cartilage-
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related genes and miRNAs, they may be strong candidates for the treatment of articular 
cartilage lesions. The results from paper I formed the basis of papers II and III. 
Paper II 
In paper II, the global miRNA expression profiles of dedifferentiating ACs and differentiating 
MSCs were compared. The first comparison was between uncultured ACs and 
chondrogenically differentiated MSCs. MiR-140-5p and miR-140-3p were found to be among 
the most highly expressed miRNAs in both uncultured ACs and differentiated MSCs. In the 
next comparison, we identified miRNAs that showed a reciprocal relationship during 
dedifferentiation of ACs and chondrogenic differentiation of MSCs. The expression of miR-
140-5p and miR-140-3p also changed the most during the dedifferentiation of ACs 
(downregulated) and the chondrogenic differentiation of MSCs (upregulated). Consequently, 
overexpression and inhibition studies of miR-140-5p and miR-140-3p were performed to 
investigate the function of these miRNAs.  
Global mRNA analysis of transiently transfected and stably transduced cells showed 
that miR-140-5p and miR-140-3p upregulated genes associated with the ECM and 
downregulated genes associated with the cell cycle and the cytoskeleton. Further, 
chondrogenesis was impaired in MSCs stably overexpressing anti-miR-140-5p. This result 
was also supported by reduced GAG secretion and reduced expression of key chondrogenic 
markers as determined by western blot. Although many ECM-associated genes were 
downregulated when miR-140-5p was inhibited, the levels of SOX9 and ACAN (aggrecan) 
mRNA were more or less unchanged. However, the protein levels were greatly reduced, 
showing that miR-140-5p positively regulates SOX9 and ACAN post-transcriptionally. Thus, 
the dramatic effect of miR-140 on cartilage development both in vivo and in vitro may be 
explained by an unknown in which miR-140 enhances SOX9 and ACAN protein levels. This 
may occur either via a direct mechanism leading to increased translation or via an indirect 
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mechanism where miR-140 targets a gene responsible for inhibition of translation or the 
degradation of the proteins in question. In addition, several possible new targets of miR-140-
5p and miR-140-3p were identified, including RALA, a small GTPase involved in TGF-
β/Activin signalling. RALA was also verified to be a target of miR-140-5p. 
 
Paper III 
Based on results reported in paper I, we wanted to investigate the function of some of the 
miRNAs that were differently expressed during in vitro culture of ACs. These included miR-
145, miR-140-3p and miR-140-5p. Surprisingly, our pilot experiments showed that a 
synthetic version of miR-145 (smiR-145), but not smiR-140-3p or smiR-140-5p, induced a 
strong immune response in both ACs and MSCs when transiently transfected with liposomes. 
Thus, it was necessary to establish a transfection method that did not induce immunological 
off-target effects for future experiments. In paper III, we report on the immunological off-
target effects observed following liposome transfection of smiR-145 into human MSCs and 
human ACs. It was also demonstrated that the immunological off-target effect was mediated 
by the cytosolic dsRNA receptor RIG-I. The immune response was dependent on liposome 
delivery, as electroporation of smiR-145 did not induce an immune response. The dependency 
of RIG-I activation on liposome delivery has not been described before, and this finding 
opens new lines of investigation into RIG-I biology. Interestingly, an immune response, albeit 
at lower level, was observed by exposing the cells to liposomes only. In contrast to the smiR-
145-induced immune response the liposome-induced immune response was not mediated by 
RIG-I. Clearly an immune response can potentially mask or change the cellular response to 
the synthetic miRNA that is used, making it very difficult to interpret the actual role of the 
miRNA under investigation. Based on these results, electroporation was the method of choice 
for transient transfection in paper II.  
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Methodological considerations 
In this section, a brief introduction and some of the advantages and limitations of the methods 
included in this thesis will be presented. I will also mention some of the main obstacles 
encountered and which problem-solving strategies we performed to overcome these problems.  
Cell culture 
All ACs and MSC donors were isolated and cultured according to standard protocols 
described in the materials and methods in papers I, II and III. When appropriate, 
dedifferentiation of ACs was demonstrated by the reduced expression of COL2A1. All MSC 
donors fulfilled the criteria for the definition of human MSCs as proposed by ISCT (210).     
Serum supplement 
Serum supplies the culture medium with factors such as fatty acids, hormones, cytokines and 
other proteins that are essential for the survival and growth of cells in culture. Proteins such as 
fibronectin are also important for attachment of the cells to the culture vessel surfaces. Foetal 
bovine serum (FBS) has long been used as a serum supplement for ACs, MSCs and other 
types of cells. However, animal-derived products may be a source of viruses, prions or 
zoonotic infections (211). The development of antibodies against bovine proteins was also 
demonstrated in patients receiving cells cultured in FBS and may lead to the rejection of the 
cells (212). If cultured cells are to be used in cellular therapy, all animal-derived products 
should ideally be excluded from cell cultures. Both allogeneic and autologous serum have 
been shown to support growth and differentiation of MSCs, and pooled human platelet lysate-
rich plasma (hPLP) is widely used in protocols for culturing cells today (213-215). During the 
last two years, our research group has humanised all cell culture procedures, and hPLP is now 
routinely used for research purposes. This procedure involved comparison between cells 
cultured in FBS and hPLP. The expression patterns of common cartilage-related genes and 
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miRNAs, including COL1A1, COL2A1, SOX9, miR-140-3p, miR-140-5p, miR-145 and miR-
221, were determined and demonstrated to have similar characteristics when FBS and hPLP 
were used as serum supplement. These data are not included in this thesis, but the results from 
papers I (FBS) and III (FBS and hPLP) reflect these findings. 
    
Alginate 
As described in the section “In vitro chondrogenesis using three-dimensional scaffolds” (page 
30), both ACs and MSCs can be cultured using a wide range of three-dimensional scaffolds. 
Alginate is a naturally occurring polysaccharide consisting of β-D-mannuronic acid (M) and 
α-L-guluronic acid (G) monomers that are distributed randomly or as repeating or alternating 
blocks of G and M (216). Divalent cations such as Ca2+, Sr2+ and Br2+ interact with G-blocks 
and form three-dimensional gels in which the cells are encapsulated. The gels are easily 
dissolved in the presence of chelating agents such as citrate or EDTA (216). Alginate has long 
been used for cell encapsulation purposes and maintains the chondrogenic phenotype of ACs 
in long-term cultures and promoting the re-expression of cartilage-specific genes in 
dedifferentiated ACs (217,218). In our laboratory, the procedures for culturing and differentiating 
MSCs in alginate have been carefully characterised, and alginate was therefore used as a 
scaffold to support in vitro chondrogenesis of MSCs in paper II (219-221). 
 
Transfection: overexpression and knockdown 
Transfection is the procedure of introducing nucleic acids into cells, and it is used for 
overexpressing and knocking down genes and miRNAs. Commonly used transfection 
methods can be classified into three groups:  1) viral or biological methods (e.g., retroviruses 
and lentiviruses), 2) physical non-viral methods (e.g., electroporation and microinjection) and 
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3) chemical methods (e.g., the use of carriers such as lipids or calcium-phosphate) (222). It is 
common to distinguish between stable and transient transfection. Stable transfection refers to 
cells that have integrated foreign DNA into their genome. The genes are therefore stably 
expressed even after replication. Transient transfection on the other hand, does not lead to 
integration into the genome. The genetic material is diluted during cell division and 
susceptible to degradation. Thus, the genetic material is only transiently expressed. Not all 
transfection methods are suitable for all cells, and huge variations in viability, transfection 
efficiency, toxicity, off-target effects and gene expression levels can be observed with 
different transfection methods. Transfection can also be highly affected by factors such as the 
culture medium, confluency, number of passages, the cell cycle and the quality of the genetic 
material used (Transfection methods overview, www.bio-rad.com/transfection). Below, some 
of the pros and cons of the transfection methods used in this thesis are briefly reviewed.  
 
Liposomal transfection 
During transient transfection using lipid-based methods, the lipid reagents are mixed with the 
nucleic acids. The lipids will then spontaneously form small vesicles (liposomes) containing 
the nucleic acids. Liposomes are thought to be taken up by endocytosis and transported via 
the endosomal pathway before releasing the nucleic acids into the cytoplasm. Fusion with the 
plasma membrane and direct delivery of the nucleic acids into the cytoplasm may also occur 
(182,183). Some of the advantages of liposome transfection are that it is easy to perform, it is not 
very expensive, and it is highly efficient in certain cell types. However, some cell types are 
very difficult to transfect with these reagents, and the reagents are toxic at high concentrations. 
As already mentioned on page 37, liposomal transfection reagents may induce unwanted 
activation of the immune system, which can potentially mask or change the cellular response 
to the nucleic acids used for transfection. Lipofectamine 2000 and siPORT Transfection 
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Agent were used for liposomal transfection in paper III. Due to activation of immune 
responses a lot of time was used for investigating this phenomenon. In the beginning we could 
not exclude the possibility that the immune response was a result of smiR-145 regulating 
target genes involved in for example innate immune responses. However, after reading 
extensively in the literature and after performing many experiments we finally found a way to 
show that the immune response was dependent on liposomal delivery. When smiR-145 was 
delivered by electroporation no immune response was observed. Investigating immunological 
off-target effects was not one of our aims when this thesis was planned. It was an unexpected 
finding, but since the results were important for obtaining reliable data and because we had 
performed so many experiments to establish a transfection method that did not induce 
immune responses we decided to investigate this phenomenon in more detail. This was the 
basis for paper III and also the reason for using electroporation for transient transfection in 
paper II.    
Electroporation 
Electroporation is a method that uses electric pulses to make transient pores in the cell 
membrane enabling nucleic acids to be transported across the cell membrane, directly into the 
cytosol without involving any active transport mechanisms (223). This method is highly 
efficient and can be used on a wide range of cells. Additionally, it is easy to perform. On the 
other hand, electroporation often results in high cell mortality. This was the main problem 
when optimizing the electroporation procedure. In order to solve this problem several 
experiments were performed. It turned out that the amount of serum used was crucial for 
survival. In our initial experiments culture medium containing 10% FBS was used. However, 
when switching to 20% FBS most cells survived. The number of cells used for each reaction 
also seemed to matter. 1x106 cells per reaction was optimal in our experiments. Higher cell 
mortality was observed when using 500.000 cells per reaction. The reason for this is not 
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known, but cell membranes may function as resistance to the electrical current used for 
electroporation. By reducing the number of cells, each cell is exposed to a higher electrical 
current (current was kept constant), which presumably contribute to cell mortality. On the 
other hand, using more than 1x106 cells per reaction the transfection efficiency was reduced. 
Although 20% hPLP was used in some electroporation experiments (paper II) there seem to 
be no difference in viability between 10% or 20% hPLP. The reason for this is unknown. The 
Nucleofection technology from Lonza (an electroporation technique in which nucleic acids 
are transferred into both the cytoplasm and nucleus) was used in papers II and III.  
 
Lentiviral transduction 
Dedifferentiation of ACs and differentiation of MSCs often involves culture periods of two to 
three weeks. Because the effect of transient transfection only last a few days, we decided to 
use stable transfection to investigate the function of miRNAs during these two processes. A 
lentiviral transduction system that utilises the third generation of replication incompetent 
HIV-based expression vectors was used for this purpose (paper II) (224). Briefly, the process 
involves transient transfection of separate viral constructs encoding all the proteins needed for 
production of viral particles and an expression vector encoding “the gene of interest” into a 
so-called packaging cell line. The expression vector is then packaged into viral particles and 
secreted into the supernatant by the packaging cells. The viral particles (supernatant) are then 
harvested and transferred to the desired target cell, resulting in infection, reverse transcription 
of the expression vector and integration into the genome of the target cells. The main 
advantage of lentiviral transduction is that both dividing and non-dividing cells can be 
transduced with high efficiency, resulting in sustainable transgene expression. However, 
lentiviral transduction is a time-consuming process, and because the viral vectors are 
integrated randomly into the genome, there is a risk of disrupting tumour suppressor genes. 
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Third-generation replication-incompetent HIV-based expression vectors have been modified 
in several ways to enhance their biosafety, and they are considered biologically safe. However, 
because these vectors can transduce human cells, there is always a risk for the investigators. 
Special laboratory facilities and practices that are in line with established health and safety 
guidelines are therefore required for experiments utilising lentiviral vectors. The main 
obstacle in optimising transduction seemed to be induction of senescence in the MSCs.  The 
cells did not proliferate more than one passage after lentiviral transduction in our initial pilot 
experiments. In an attempt to solve this problem, serum source, cell number, different MOI 
(Multiplicity of Infection) and several concentrations of transduction reagents was 
investigated. Transduction using hPLP as serum supplement resulted in much lower 
transduction efficiency compared to FBS in all experiments. Thus, incubation with viral 
particles overnight was performed using FBS as serum supplement. Polybrene and puromycin 
are often used in transduction experiments to increase transduction efficiency and as a 
selection antibiotic for transduced cells, respectively. High doses of both polybrene and 
puromycin seemed to induce senescence in the MSCs in our pilot experiments. By reducing 
the amount of polybrene and puromycin and increasing the MOI we were able to transduce 
MSCs with high efficiency and culture the cells for at least two to three passages after 
transduction. The transduced cells were also successfully differentiated into chondrocytes for 
three weeks and adipocytes and osteocytes for four weeks. The MOI and concentration of 
transduction reagents used in paper II were based on results from pilot experiments performed 
over several weeks. Compared to MSCs, ACs did not undergo senescence in any of the 
experiments. However, the same transduction conditions were used for both cell types in 
paper II.  
 
52 
 
Reverse transcription-quantitative real-time polymerase chain reaction (RT-
qPCR) 
RT-qPCR is one of the most powerful methods for quantification of RNA due to its high 
specificity, sensitivity and reproducibility. The process of RT-qPCR involves four steps: (1) 
preparation of RNA, (2) reverse transcription (RT) to cDNA, (3) amplification of cDNA by 
PCR and (4) data analysis (225). During the first PCR cycles, the cDNA template is doubled, 
resulting in exponential amplification. Thereafter, primarily because of reagent limitations, 
the PCR reaction slows down and the PCR product is no longer doubled at each cycle. In the 
exponential phase, the PCR products formed are directly proportional to the amount of RNA 
template in the starting material (226). RT-qPCR measures the amount of PCR products formed 
in the exponential phase, making it possible to determine the initial amount of target RNA in 
the starting material. The detection and quantification is possible because of fluorescent dyes 
or probes that bind to the PCR products formed after each PCR cycle. The intensity of the 
fluorescent signal is detected by the RT-qPCR machine and reflects the amount of PCR 
product formed. For the quantification of mRNA and miRNA, two methods can be performed: 
absolute quantification (AQ) and relative quantification (RQ). AQ determines the exact 
number of target RNA molecules present in the starting material by comparison with standard 
curves (226). On the other hand, RQ uses mathematical equations and determines the change in 
expression relative to a reference sample, such as an untreated sample, without requiring the 
exact number of target RNA molecules (226). In this thesis, RQ was used for all RT-qPCR 
analyses. There are certain requirements for the RQ data to be valid. First, it is important that 
the amount of cDNA formed in the RT reaction reflects the amount of RNA input (227). If too 
much RNA is used in the RT reaction, not all RNA will be reverse transcribed to cDNA due 
to a lack of reagents or the presence of inhibitors within the sample. This may lead to false 
values. This can be tested by preparing a dilution series of the RNA (227).One of the first pilot 
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experiments I performed in our laboratory was to test this using five different concentrations 
of RNA input. Not in any of the experiments did I observe any problems related to RNA input. 
We do not test this in every single experiment performed in our laboratory, but the pilot 
experiments indicate that this is not a common problem in the experimental settings used in 
this thesis. Second, for normalisation of RT-qPCR data, an internal reference gene is 
amplified simultaneously as the target gene. The expression level of the reference gene has a 
huge impact on the results, and it should ideally be expressed at constant levels in all samples 
investigated. Therefore, it is highly recommended that reference genes be validated for each 
experiment to ensure constant expression within all samples used for comparisons (228). This 
was an issue in paper I where uncultured ACs had very different expression of typically used 
internal reference genes compared to cultured ACs. Actually we had to test thirty-two 
different internal reference genes before we found one that was expressed at similar levels in 
both uncultured and cultured ACs. Interestingly, we have observed exactly the same in 
uncultured and cultured human endothelial cells. Third, the RQ method is only valid if the 
amplification efficiency of both the target gene and the reference gene is approximately equal 
(above 90%). This can easily be assessed by diluting the RNA from each sample and looking 
at how the results vary relative to the dilution, as previously described (226). In our RT-qPCR 
analysis we have used Taqman gene expression assays. These assays have been validated by 
the manufacturer to have the same amplification efficiency. However, we have checked the 
amplification efficiency of some of the assays we routinely use in our experiments using the 
method described by Arya et al. (226). All accept one showed similar amplification efficiency. 
This assay on the other hand was not used in this thesis. RT-qPCR analysis is fast, and when 
properly performed, it is one of the most sensitive and powerful methods for RNA 
quantification. Because gene expression can be regulated at many steps, from the genome 
(genes) to the final protein product (12), the major drawback of RT-qPCR and other RNA 
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quantification methods is that RNA levels do not always reflect the corresponding protein 
levels (229). In these situations, RNA quantification is not always useful.   
 
Global mRNA and miRNA analysis 
Global gene expression analysis is one of the most widely used methods in biology today, and 
it provides quantitative information about the transcriptome of cells (230). Both mRNA and 
miRNA transcriptome profiling were performed in this thesis. In this type of approach, most 
genes and miRNAs are represented as oligonucleotides on a small array. The samples are 
usually reverse transcribed to cDNA or cRNA and labelled with biotin (or a fluorescent dye) 
and applied to the array. Because of the hybridisation properties of nucleic acids, the labelled 
nucleic acids will bind to their complementary strands on the array. After washing away non-
hybridised material, the arrays are stained with a streptavidin-Cy3 conjugate (streptavidin 
binds biotin and Cy3 emit fluorescence). After another washing step, the array is placed in a 
scanner that measures the amount of fluorescent signal created. The intensity of the 
fluorescent signal is proportional to the amount of mRNA/miRNA in the original sample.  
One of the main advantages of transcriptome profiling analysis is that thousands of genes can 
be studied simultaneously, making it possible to identify new genes that are important for 
different biological processes. It is also relatively cheap and quite fast. However, there are 
many possible sources that can contribute to errors in microarray analysis, such as sample 
collection, labelling, hybridisation efficiency and fluctuation in scanning the fluorescent 
signal (231). Transcriptome profiling provides huge data sets that need to be analysed carefully. 
Several statistical and data analysis tools are available for this purpose. It is important to use 
these tools carefully and keep the sources of variation in mind when processing the data. As 
with RT-qPCR, transcriptome profiling only provides quantitative data for RNA molecules 
and not their encoded proteins. The Norwegian Microarray Consortium performed several 
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quality controls on our microarray data as described in paper II and III. In this thesis the J-
express software was used for analysing microarray data. The software is user friendly and is 
free of charge. Several members of our group, including me, have attended a course to learn 
how to use this software. Microarray analysis software can be used to analyse data in several 
ways using different methods and statistical algorithms. For our studies we chose to make 
simple gene lists of differently expressed genes and gene ontology analysis in order to classify 
the genes according to functionality. To ensure that our analysis was correctly performed we 
also went through our experimental strategy and analysis together with a bioinformatician 
from The Norwegian Microarray Consortium.  
 
Flow cytometry 
Flow cytometry is used to measure the fluorescence and optical properties of cells (and other 
particles) contained in a single-cell suspension. Within a stream of fluid, single cells flow 
through the beam of a laser. Light is then emitted and scattered in all directions. The forward 
scattered light gives information about cell size, while the side scattered light gives 
information about the intracellular granularity of the cells. With the use of fluorescent dyes or 
fluorescent conjugated-antibodies, it is possible to measure the DNA and RNA content, 
enzyme activity, membrane potential, intracellular calcium flux, the levels of intracellular 
proteins and proteins expressed on the cell surface (232). Flow cytometry analysis is rapid and 
provides quantitative data. Another advantage is that it is possible to study subpopulations 
within a heterogeneous cell population.  The principles of flow cytometry can also be 
exploited to sort and isolate cells with great precision. This technique is called fluorescence 
activated cell sorting (FACS). Although flow cytometry can be used for many different 
applications, it also has some limitations. Flow cytometry requires cells to be in suspension, 
meaning that cells inside tissues have to be released in order to be analysed. The software and 
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the analysis can be quite sophisticated, and advanced analysis requires highly skilled 
operators. It is also important to ensure the specificity of the antibodies used to avoid 
nonspecific binding to other proteins. This can in some situations be checked by western blot 
analysis (233)). Flow cytometers are also quite expensive. The experimental settings used for 
flow cytometry in this thesis were straight forward, and I did not run into problems in these 
analyses. However, sorting of cells in paper II was performed by The Flow Cytometry Core 
Facility at Oslo University Hospital as we had little experience with this procedure. 
 
Multiplex bead array assay 
Multiplex bead array assay analysis is based on many of the same principles as flow 
cytometry (fluidics, laser, optics and the use of antibodies), and it can be used to detect many 
different proteins in the same sample at the same time. Small beads of two colours and with 
different intensities are coated with capture antibodies against specific proteins and then 
mixed with the sample (such as cell culture supernatants, serum or cell lysates). The protein 
bound by the capture antibody is then detected using a fluorescent-coupled reporter antibody. 
Because of the different colour intensities of the beads, each bead coupled with a specific 
capture antibody can be identified, while the signal intensity from the fluorescent-coupled 
reporter antibody is used for quantification of the protein. The combination of these two 
features makes it possible to measure 100 proteins in the same sample. Two lasers are used 
for this purpose. Multiplex bead array is a quantitative method, and it uses very small sample 
volumes. For large-scale analysis, this approach will reduce both the cost and time required 
compared to enzyme linked immunosorbent assay (ELISA), which has been the standard 
method for quantitative analysis of cytokines and other proteins. Although it has been shown 
to be comparable with the widely used ELISA (234), the sensitivity of bead assays from 
different suppliers has been questioned (235). In this thesis multiplex bead array assay was 
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performed as a small part of paper III. Both the experimental procedure and the data analysis 
were performed under supervision of Julie Katrine Lindstad who is a highly experienced user 
of this system.  
 
Western blot (immunoblot) 
Western blot is a widely used method that utilises antibodies for the detection of proteins in 
tissue samples, serum, cell lysates or cell culture supernatants. The technique involves 
separation of the proteins according to their size by electrophoresis and transfer of the 
separated proteins onto a polymer membrane using an electrical current. A primary antibody 
against the protein of interest is then added to the membrane. After washing away unbound 
primary antibodies, a labelled secondary antibody is added. The labelled secondary antibody 
recognises the primary antibody, which is bound to the protein, and it emits a signal that can 
be detected. This is a typical set-up, but there are other set-ups as well (Alegria 2009). The 
signal developed depends on the labelling technique. The labelling approach may involve 
radioactivity, chemiluminescence, fluorescence or colloidal gold. The signals are developed 
using X-ray film or detection machines that create a digital image of the signals. Traditional 
western blots are considered to be semi-quantitative, but by use of proper controls, this 
method can be used for quantitative analysis (236). Western blotting has a very high specificity 
and sensitivity. However, the procedure involves many steps and reagents, and each step has 
to be optimised for successful detection and identification of the desired protein. The major 
obstacle with western blot analysis in this thesis was to extract proteins from cells cultured in 
alginate discs. Releasing the cells from the alginate disc using sodium citrate or EDTA was 
not successful, as most cells were lost during the procedure. Several other procedures were 
tried without success, including pulverising the alginate disc in liquid nitrogen and extraction 
of proteins using the Trizol method. This method included precipitation and solubilisation of 
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the proteins. However, we were not able to solubilise the precipitated proteins. At the end it 
turned out that a relatively simple procedure of pulverising the alginate disc in liquid nitrogen 
and resuspending the cell/alginate powder directly in the loading buffer (laemmli) worked 
very well. Still, the western blot bands obtained from cells cultured in alginate were less 
distinct than from cells in monolayer cultures, particularly ACAN bands.  
 
Immunohistochemistry/immunofluorescence  
Immunohistochemistry (IHC) is a technique that utilises antibodies to investigate the 
localisation and distribution of proteins (or other structures) in tissue samples. IHC is 
performed by using either fluorescence-coupled or enzyme-coupled antibodies. The principle 
is the same for both methods. The procedure involves fixation and sectioning of the tissue 
sample, incubation with primary antibodies, washing away unbound antibodies, incubation 
with secondary antibodies, washing and development of the signal. A fluorescence 
microscope is used to both detect the signal and to determine the localisation of the protein. 
Most fluorescent microscopes contain filters that make it possible to visualise different 
colours. By using secondary antibodies coupled with fluorochromes with different emission 
spectra, it is possible to visualise different proteins in the same cell. The ability to determine 
the exact location of specific proteins in the cell is the major advantage of IHC. The major 
limitation is the potential for non-specific binding of the antibodies. Therefore, antibody 
specificity should be validated before use (for example by western blotting). Similarly to 
western blotting, the IHC procedure involves many steps and each step has to be optimised 
for successful detection. Fixation of the tissue is the most critical step in the procedure. 
Fixation is performed to conserve the architecture, or morphology of the tissue, but 
unsuccessful fixation may result in artificial staining patterns. Thus, optimisation using 
several fixation reagents is recommended. Extensive optimisation of this procedure on 
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alginate discs and validation of all antibodies used in this thesis were performed over a period 
of several months. This work was performed by a former colleague, Axel Küchler, who has 
great knowledge and experience with this technique.    
 
MiRNA luciferase reporter assay 
Today, the only method available to validate an mRNA sequence as a binding site for a 
specific miRNA is the use of reporter genes containing the potential binding site (237). 
MiRNAs bind to complementary sequences within the mRNA (most often the 3’UTR), 
resulting in degradation of the mRNA or translational inhibition. To validate an mRNA 
sequence as a miRNA target, the 3’UTR of the mRNA (or other potential target sequences) 
can be cloned into a plasmid constitutively expressing luciferase, which emits light. When this 
construct is co-transfected together with a miRNA mimic, the light output will be reduced if 
there is a binding of the miRNA mimic to the 3’UTR.  A commercially available reporter 
assay was used to validate the targets of miR-140-5p in paper II. These commercial kits are 
quite expensive, but they reduce the amount of work required because the 3’UTR is already 
cloned in the luciferase plasmids. The procedure is very fast and easy to perform. We did not 
experience any problems using this assay.   
 
Quantification of sulfated proteoglycans and glycosaminoglycans (GAGs) 
In paper II, the sulfated proteoglycans and GAGs present in the culture medium of 
chondrogenically differentiated MSCs were quantitated using a commercial kit. The kit is 
based on a quantitative method in which a blue dye (Blyscan) turns pink when it binds to 
sulfated GAGs. By comparing the unknown concentration in the sample with a calibration 
curve made of standards with a known concentration, the amount of sulfated proteoglycans 
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and GAGs in the medium can be determined. This is a standard method used for this purpose, 
and it has been used in our laboratory for several years. The removal of insoluble materials, 
such as ECM molecules or cell debris, is crucial for obtaining reliable results, as these 
materials can interfere with the assay. It is a very fast, easy and robust procedure. No 
troubleshooting was required in these analyses.  
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General discussion 
Articular cartilage is a highly specialised tissue with poor healing capacity. Injury to the 
articular cartilage results in pain and stiffness of the joints and strongly affects the quality of 
life for many people worldwide. Several surgical strategies have been developed and are used 
to treat patients today, but the repair tissue does not consist of hyaline cartilage; rather it is 
fibrocartilage or a mix of fibrocartilage and hyaline cartilage (52). This repair tissue does not 
have the properties of hyaline cartilage and often degrades over time (44). Thus, the goal in the 
field of cartilage repair is to develop a treatment that results in the formation of perfect 
hyaline cartilage that integrates with the surroundings of the lesion and last for the rest of the 
patient’s life. ACI, one of the most widely used cell-based treatments for cartilage lesions, 
involves isolation and monolayer expansion of autologous ACs (53). A major limitation with 
ACI is that monolayer expansion of the ACs result in the dedifferentiation and loss of the 
hyaline cartilage phenotype (56,57). Avoiding dedifferentiation may be crucial for improving 
ACI. Another strategy is to use MSCs that have the capability for chondrogenic 
differentiation (90). However, there were no differences in the clinical outcomes between 
patients receiving MSCs or ACs for ACI, suggesting that both approaches result in the 
formation of a similar repair tissue (238). Understanding the molecular mechanisms leading to 
dedifferentiation and chondrogenic differentiation may result in new strategies to improve the 
clinical outcome of cartilage repair.  
 
Papers I and II 
When this thesis was begun, our group had recently published a paper showing that ACs 
cultured within their own ECM synthesised type II collagen for approximately two weeks 
before starting to spread out onto the culture surface and dedifferentiate (239). Inspired by these 
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results, we decided to characterise these cells in more detail. At that time, not many studies 
had investigated the role of miRNAs in cartilage, and no studies investigating changes in 
miRNA expression during in vitro culture of ACs were available. As miRNAs are known to 
regulate many cellular processes, we wanted to investigate the changes in miRNA expression 
occurring during in vitro expansion of ACs.  
In paper I, uncultured ACs were established in culture and expanded as previously 
described (239). We then investigated the cells at different time points with respect to their 
expression of a large number of genes, miRNAs and proteins. As described in paper I, the 
ACs went through three stages during 28 days of in vitro culture: (1) primary, uncultured ACs 
(day 0); (2) the chondroblast-like stage (day 7–14); and (3) the dedifferentiation stage at the 
end of the culture. In most ACI procedures, ACs are expanded as monolayer cultures from the 
day of isolation, resulting in implantation of dedifferentiated ACs (52,240). By expanding the 
ACs in their own ECM, sufficient numbers of cells required for ACI are obtained within two 
weeks (239). These cells are not dedifferentiated, as they express high levels of several 
collagens and transcription factors related to hyaline cartilage (paper I, Figure 1). Compared 
to fully dedifferentiated ACs, implantation of chondroblast-like cells may lead to a repair 
tissue that is more similar to hyaline cartilage. Today, ACs to be used for ACI are cultured in 
this way in our GMP laboratory. Notably, during the development of OA, the degradation of 
type II collagen and aggrecan are accompanied by a phenotypical change in which the ACs 
express molecules associated with matrix mineralisation, including type X collagen (241). Thus, 
matrix degradation seems to trigger hypertrophic differentiation. In addition, the synthesis of 
type II collagen and aggrecan are also observed during early OA, perhaps to compensate for 
the loss of these molecules, but the proteins are often degraded or damaged (242-244). This 
situation resembles some of the gene expression changes observed in paper I (Figure 1). 
When ACs are harvested and isolated for ACI, the cells are enzymatically released from the 
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cartilage biopsy. This obviously involves degradation of the matrix. Perhaps ACs released 
from the matrix are stimulated so that hypertrophic differentiation is set to be the default 
pathway. If so, it is possible that chondroblast-like cells will not be any more effective than 
fully dedifferentiated ACs. This possibility was not investigated in this thesis and needs to be 
validated in in vitro and clinical trials.  
As miRNAs were likely to be differently expressed during in vitro culture, a global 
miRNA analysis was performed in cells at each of the three stages. Several miRNAs were 
downregulated during culture of ACs, including miR-30d, miR-210, miR-451 and miR-563 
(paper I). The miR-30 family has been shown to target RUNX2 and SMAD1 and negatively 
regulate osteoblast differentiation (245). The function of miR-210 and miR-563 in cartilage 
development is unknown. However, miR-210 is considered to be the major hypoxia-inducible 
miRNA (246) and is upregulated during chondrogenesis both in vivo and in vitro (168) (paper II). 
miR-210 also promotes osteoblast differentiation by inhibiting TGF-β/activin signalling (247). 
Nevertheless, as ACs experience hypoxic conditions in vivo, it is reasonable to suggest an 
important role of miR-210 in cartilage biology. 
Some of the miRNAs that were upregulated during the dedifferentiation of ACs 
included miR-132, miR-138, miR-145, miR-221 and miR-222. We also reported the possible 
targets of several of these miRNAs, including SOX9 as a target of miR-145 and SOX5 and 
SOX6 as targets for miR-132 and miR-138, respectively. Since then SOX9 has been verified 
as a target of miR-145 in two studies (162,163) In bovine articular cartilage, miR-222 plays a 
role in mechanotransduction (164), while miR-221 has been reported to be a negative regulator 
of chondrogenesis in chick limb mesenchymal cells (165). In paper I, miR-140-3p and miR-
140-5p were reported to follow the expression pattern of SOX9 (downregulated during 
dedifferentiation). At that time, miR-140 was already known to be cartilage-specific and 
important for the development of pharyngeal cartilage in zebrafish. Indications also suggested 
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that SOX9 regulated the expression of miR-140, which was in line with our findings (151,152,248). 
During our preparation of paper I, two articles on miR-140 were published by the same group 
(156,249). The first paper compared miRNA expression in ACs with that of undifferentiated 
hMSCs and found miR-140 to have the largest difference in expression between the two cell 
types. In addition, miR-140 was reduced in OA compared with healthy articular cartilage and 
was downregulated by the OA-associated cytokine IL-1β (249). The second paper demonstrated 
an important role for miR-140 in cartilage homeostasis and cartilage development as 
described on page 34. Briefly, miR-140 knockout mice were shown to have a shorter skeleton 
and an OA-like pathology, and ADAMTS5, an aggrecanase, was validated as a target of miR-
140 (156). Immediately following the publication of paper I, SOX9 was confirmed to positively 
regulate miR-140 transcription (153). Clearly, miR-140 had a profound effect on cartilage 
development, but the main mechanism had not been demonstrated. In paper II, we compared 
the miRNA expression profiles of chondrogenically differentiated MSCs and uncultured ACs. 
MiR-140-5p and miR-140-3p were among the most highly expressed microRNAs in both 
differentiated MSCs and uncultured ACs, and their expression changed the most during 
culture (paper II, Figure 1, Table 1 and Supplementary Table S4 ). At the global mRNA level, 
several genes encoding cartilage/ECM molecules were downregulated after inhibition of miR-
140-5p, while genes associated with the cell cycle and cytoskeletal remodelling were 
upregulated. Further, inhibition of miR-140-5p inhibited GAG synthesis in differentiating 
MSCs and SOX9 and ACAN were downregulated at the protein level, although no consistent 
differences were observed at the mRNA level. It is well known that miRNAs may directly 
regulate gene expression at the translational/protein level (250-252). In paper II we found 
potential binding sites for miR-140-5p in the 5’-UTR of both SOX9 and ACAN mRNA. miR 
binding to the 5’-UTR has previously been associated with translational enhancement (251,252). 
Thus, the positive post-transcriptional regulation of these molecules may occur via a direct 
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mechanism leading to increased translation. Another possibility is an indirect mechanism 
where miR-140 targets a gene responsible for inhibition of translation or the degradation of 
the proteins in question. This result demonstrates how important it is to analyse protein levels 
when investigating miRNAs. In many situations, there is no correlation between the mRNA 
and protein levels (229). Microarray analysis may be useful as a screening tool to look for 
miRNA targets and assess the global effect after manipulation of miRNAs. However, 
important regulatory molecules may be overlooked, and it is highly recommended to at least 
investigate protein levels for key regulators of the processes being studied. The huge effect on 
SOX9 and ACAN proteins and chondrogenesis was perhaps not obvious compared to the 
levels of miR-140-5p inhibition after anti-miR-140-5p treatment (paper II, Figure 5a). 
Notably, the lentiviral vector used for inhibition of miR-140-5p produces an RNA that is fully 
complementary to endogenous miR-140-5p. The complementary RNA binds the endogenous 
miR-140-5p and forms a thermodynamically stable duplex and thereby inhibits its function by 
preventing miR-140-5p from binding its targets. The anti-miR molecules are not expected to 
degrade endogenous miRNA levels. Thus, the reduced miR-140-5p levels measured after 
inhibition also included the bound and inhibited miR-140-5p and are therefore likely to be an 
underestimation. The reduced levels of miR-140-5p in paper II (Figure 2B and Figure 5A) are 
most likely a result of reduced transcription due to the reduced SOX9 protein levels and not a 
result of degradation. This is also supported by the fact that miR-140-3p (which should not be 
a target of anti-miR-140-5p) is reduced to more or less the same levels as miR-140-5p (paper 
II, Figure 2B) 
The data from paper II support the results from earlier in vivo studies in which miR-140 
protects against proteoglycan loss and the development of OA (156). Not surprisingly, miR-140 
is downregulated in osteoarthritic cartilage (172,249). Recently, reduced levels of miR-140 were 
also detected in the synovial fluid of OA patients compared to control samples (253). As miR-
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140 is regarded as a tissue-specific miRNA and has such a dramatic effect on cartilage 
homeostasis, it has the potential to serve as a biomarker for the development of early OA. 
MiR-140 can also be detected in the plasma and other tissues beside cartilage, showing that its 
expression is not restricted to cartilage tissue (254,255). Regardless, if miR-140 from the 
synovial fluid or plasma can be used as a biomarker to predict early OA, it would provide a 
very easy and cheap method that could improve treatment and be of great help in the effort to 
understand the underlying causes of OA (256). 
Apart from miR-140-5p and miR-140-3p, several other miRNAs were differently 
expressed between uncultured ACs and differentiated MSCs (paper II). Among the top 100 
expressed miRNA between the two cell types, 57% were common to both cell types. Thus, 
many of the miRNAs expressed or induced by in vitro chondrogenesis may in fact be 
undesirable as they are not expressed in uncultured ACs. These miRNAs may even be 
responsible for the expression of proteins such as type I and type X collagen that are present 
during chondrogenic differentiation of MSCs (220). One example is miR-181a, which promotes 
type X expression in pre-hypertrophic/hypertrophic chondrocytes (oral presentation: IADR 
General Session, Barcelona, Spain, July 14-17, 2010). MiR-181a was barely detected in 
uncultured ACs, but it was highly upregulated during chondrogenic differentiation of MSCs 
(paper II). One strategy to improve chondrogenesis for tissue engineering purposes may be to 
inhibit miRNAs that are not expressed in native cartilage but highly expressed in the 
differentiating cells or to overexpress miRNAs that are highly expressed in native cartilage 
but not expressed in differentiating cells. As shown in paper II, one miRNA can regulate 
hundreds of genes, demonstrating the potential use of miRNAs in therapeutics and cartilage 
repair. Another strategy is to manipulate more than one miRNA. By overexpressing the miR-
302/367 family, Anokye-Danso et al. showed that somatic cells could be reprogrammed into 
iPSCs with similar characteristics as ESCs, including germline and chimera contributions (257). 
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These findings demonstrate the powerful effect of miRNAs. Manipulating only a few 
miRNAs enabled cells to completely change their epigenetic landscape and transcriptome and 
in essence become another type of cell. Perhaps manipulating only one or a few miRNAs will 
aid in developing cartilage cell therapies that eventually relieve the suffering of millions of 
people.      
 
Paper III 
Paper III is not directly related to chondrogenesis and dedifferentiation but is more concerned 
with the methods used for investigating miRNA functionality. These results were very 
important for us to continue our work to investigate the function miRNAs.  
As already discussed in paper I, miR-145 was highly upregulated during 
dedifferentiation and showed an inverse relationship with SOX9 expression. Bioinformatic 
analysis also identified SOX9 as a potential target of miR-145 (paper I). Based on our own 
findings and published data, we decided to continue our investigation of several miRNAs, 
including miR-145. To identify targets and unravel the molecular mechanisms of chondrocyte 
dedifferentiation, we subsequently performed pilot experiments in which liposome-mediated 
transient transfection was used to overexpress and inhibit miRNAs in ACs and MSCs. 
Surprisingly, a strong immune response against a synthetic miR-145 mimic (smiR-145) was 
observed, but not against any other sequences tested. Previously, it was shown that siRNAs 
(very similar to synthetic miRNAs) induced immune responses through TLRs located in 
endosomes (192). Understanding the mechanisms behind these responses and avoiding them is 
important for obtaining reliable data that are specific to the microRNA investigated. Clearly, 
liposome transfection could lead to misleading results. For example, siRNAs against VEGF 
were shown to inhibit vascularisation in mice (258). However, it was demonstrated that 
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different control siRNAs targeting non-mammalian and non-expressed genes had the same 
effect due to stimulation of interferons (259). 
We therefore decided to investigate this phenomenon in more detail and to see if it was 
possible to avoid the immune response. Thus, the objective of paper III was not to investigate 
the specific role of miR-145 as a miRNA, but rather to understand its immunological off-
target effects. As shown in paper III, the smiR-145-induced immune response was mediated 
by RIG-I and was dependent on liposomal delivery, as electroporation of smiR-145 did not 
lead to an immune response in either MSCs or ACs. Based on these results, we decided to use 
electroporation for transient transfection in paper II. 
Perhaps the most surprising result in paper III is that RIG-I required liposomal delivery for 
activation in certain situations. This has not been described before. It has been proposed that 
once foreign RNA is located in the cytoplasm, it will be recognised by RIG-I independently 
of the delivery mechanism and immediately induce an immune response as a defence 
mechanism against viruses. Liposomal delivery utilises the same pathways as many viruses 
for entering cells (182-184,260). There are two main routes for virus entry. The first is the 
endocytic route in which viruses enter cells via endocytosis and are transported through the 
endosomal pathway. The other route is the non-endocytic route, which involves fusion with 
the plasma membrane and direct entry into the cytoplasm (261). It is already known that 
endosomal TLRs respond to viruses entering the endosomal pathway (191). Perhaps the role of 
RIG-I is to survey the actual entry point of the non-endocytic route instead of keeping the 
entire cytoplasm under surveillance as previously thought. This would be a much more 
efficient strategy. However, this hypothesis needs to be investigated further. In any case, the 
choice of delivery method does affect the ability of RIG-I to respond to certain RNA 
sequences. For researchers investigating RIG-I biology, this possibility should be of interest 
for further investigation.  
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It is well known that cells secrete small vesicles (exosomes) containing miRNA, 
mRNA and proteins that are taken up by neighbouring cells. MSCs express high levels of 
endogenous miR-145 (paper III, Supplementary figure S3), and they secrete exosomes (262). In 
theory, exosomes containing endogenous miR-145 could activate an immune response via 
RIG-I when taken up by neighbouring cells. The sequence of smiR-145 is identical to the 
endogenous miR-145, and it could be speculated why MSCs do not persistently express 
immune genes when they express very high levels of endogenous miR-145 and if RIG-I reacts 
with self-RNA. Although it has been suggested that RIG-I is involved in sensing self-RNA 
(263), it is not likely to be the case with endogenous miR-145. First of all, untransfected MSCs 
do not express CXCL10 (paper III, Figure 1). If exosomes induced an immune response, 
MSCs should constantly express CXCL10. Second, exosomes secreted by MSCs actually 
possess an immunosuppressive activity (262). One explanation could be that these exosomes do 
not contain miR-145 and therefore do not induce an immune response. On the other hand, it is 
known that chemical modification of siRNAs inhibits immunological off-target effects 
(judge), and more than 100 natural chemical modifications of endogenous RNA have been 
described so far (264). Although the sequences of smiR-145 and endogenous miR-145 are 
identical, they are definitely not identical with regards to chemical modification. Such 
naturally occurring modifications may indeed be used to distinguish self from non-self RNA 
(265). In other words, if it was possible to transfect endogenous miR-145 using liposomes, 
RIG-I would probably not be activated by miR-145. In my opinion, this is a more likely 
explanation for the lack of a persistent immune response in MSCs. In paper III, 5’ppp and 
blunt ends versus 2’nucleotide overhangs were discussed as possible mechanisms for 
discriminating between self and non-self RNA. Natural chemical modification is yet another 
mechanism by which the cell can discriminate between self and non-self RNAs. 
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Immunological off-target effects may not only lead to biased results, but they also 
raise concerns about the safety of these reagents for potential use in clinical trials. However, 
in certain circumstances such as cancer therapy, viral infections and vaccine development, 
stimulating an immune response may be desirable. Interferons inhibit angiogenesis and have 
been used for the treatment of cancer for a long time (266).  Several studies have therefore 
explored the possibility of using immunostimulatory nucleic acids for cancer therapy (267). 
TGF-β1 is elevated in tumours and is therefore a potential target in cancer therapy. Recently, 
Ellermeier et al. combined the silencing effect of siRNA against TGF-β1 and immune 
activation via RIG-I to study the effect in a mouse model of pancreatic cancer. By adding 
5’ppp to the TGF-β1 siRNA, the mouse immune system was activated, and prolonged 
survival compared to mice that received an unmodified TGF-β1 siRNAs and a 5’ppp-control 
siRNA. Notably, both unmodified TGF-β1 siRNAs and a 5’ppp-control siRNA reduced 
tumour formation compared to unmodified control siRNA (268). 
INF-β was one of the molecules that were highly expressed after liposomal 
transfection of smiR-145. It has been suggested that INF-β can be used for treatment of 
arthritis (269). Thus, manipulating miRNAs involved in arthritis with immunostimulatory 
miRNA mimics or inhibitors could potentially be used in therapy using the same strategy as 
that described by Ellermeier et al. 
Liposomes and immunostimulatory nucleic acids have also been explored and used as 
adjuvants for vaccine development (270-272). In vaccine development, the goal is to induce an 
immune response against a specific antigen to provide long-term protection against infection. 
Adjuvants are substances that are used in combination with the antigen to enhance or improve 
the immune response to the antigen. As shown in paper III and elsewhere (184-186), liposomes 
induce an immune response, but liposomes alone are not sufficient to activate antigen-
presenting cells, which are important for developing effective vaccines (271). On the other hand, 
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activation of antigen-presenting cells can be achieved by stimulating PRRs (271,272). The 
combination of liposomes with immunostimulatory smiR molecules may therefore be a 
strategy for improving vaccine development (271). However, effective use of liposomes and 
immunostimulatory smiR molecules in therapy will require a detailed understanding of the 
immunological properties of each reagent (272). Currently, it is difficult to predict which 
sequences will induce immune responses and how strong the response will be. Such responses 
will also vary between cell types, making this a complicated task.  The recently established 
RNA immuno database provides an opportunity to analyse and compare the results of studies 
using RNA inhibition techniques and may be used as a guide to avoid or minimise 
immunological off-target effects, but it may also be useful for predicting immunological off-
target effects in therapy (273). The data in paper III may result in a better understanding of 
RIG-I biology in the future and will hopefully contribute to our understanding of how the 
manipulation of miRNAs can be safely used in clinical protocols. 
The liposome-induced immune response reported in paper III was different from the 
smiR-145 response and included the production of inflammatory cytokines such as interleukin 
6 (IL6), IL8 and IL-1β (paper III, Figure 8a,b). Others have also reported this phenomenon, 
and recently it was shown that such liposome-induced immune responses involved STING, an 
ER-resident transmembrane protein (184). Although the receptor for the liposome-induced 
immune response has not been identified in our study, TLR4 or lipid receptors in the plasma 
membrane may be involved (188-190). This observation may lead to a better understanding of 
the early events in the development of atherosclerosis. Atherosclerosis is considered as an 
inflammatory disease and results in the deposition of lipids in arteries and may eventually 
lead to blockage of the arteries and myocardial infarction (274). At an early step in the process 
of atherosclerosis, endothelial cells are activated by lipids, resulting in secretion of 
inflammatory chemokines, including CCL5, CXCL10, IL6, IL8 and IL1β, which was also 
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upregulated by liposomes as shown in paper III (Figure 1, 2 and 8) (274-276). In the 
atherosclerosis field, much attention has been focused on PRRs because cholesterol has been 
shown to upregulate IL1β, which is considered to be the gate-keeper of inflammation (277-279). 
The mechanisms mediating these responses are not fully understood (274), but it is possible that 
physiological lipids induce an immune response in the same way that the liposomes in our 
experiments did. This is one of the follow-up studies that our group is planning to undertake.  
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Conclusions 
1. Chondroblast-like cells expressed genes and synthesised proteins typical of hyaline 
cartilage. Whether these cells will produce better hyaline cartilage than dedifferentiated 
chondrocytes or MSCs needs to be tested in formal assays for in vitro chondrogenesis and, 
eventually, in clinical trials. 
 
2. Several miRNAs were differently expressed during dedifferentiation of ACs. Many of the 
miRNAs were predicted to have key chondrogenic genes as targets. 
 
3. Chondrogenically differentiated MSCs and uncultured ACs expressed many of the same 
miRNAs but were quite different at the global level. Furthermore, several miRNAs 
showed a reciprocal relationship during dedifferentiation of ACs and chondrogenic 
differentiation of MSCs. 
 
4. MiR-140-5p had a profound impact on chondrogenesis and positively regulated SOX9 and 
ACAN post-transcriptionally via an unknown mechanism. Moreover, global mRNA 
analysis also indicates the involvement of miR-140-5p in cytoskeleton remodelling and 
cell division. 
 
5. RALA was confirmed as a new target of miR-140-5p and may play an important role in 
cartilage biology. 
 
6. In transient transfection experiments, the choice of delivery vehicle is crucial for avoiding 
off-target effects such as immune gene perturbation that can potentially mask or change 
74 
 
the cellular response to the synthetic miRNA used. However, in certain clinical situations, 
such immune responses may be beneficial.  
 
7. smiR-145 induced an immune response via RIG-I and was dependent on liposomal 
delivery as no immune gene expression changes were observed after delivery of smiR-145 
directly into the cytosol using electroporation. Further, the liposome-induced immune 
response was different from the smiR-145 response and was not mediated by RIG-I. 
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Future studies 
Scientific discoveries not only answer questions, but they also raise new questions to be 
answered. Here, I will mention some of the potential new studies that may be worth 
investigating further based on the findings in this thesis. 
 
 
1. Besides miR-140-5p and miR-140-3p, the expression of several other miRNA also 
changed during in vitro culture of ACs and MSCs. The investigation of these miRNAs 
could reveal new and interesting biology. Such studies could also be extended by 
manipulating several miRNAs at the same time.   
 
2. Performing ACI in an animal model with cells overexpressing miRNA mimics/inhibitors. 
In vitro studies are useful, but they do not always reflect what will occur in the body. In 
vivo studies would provide data that are more relevant for the clinical use of these cells. 
 
3. Identify the mechanism responsible for post-transcriptional regulation of SOX9. This is an 
important goal of our future projects.  
 
4. RALA was validated as a new target of miR-140-5p. Interestingly, RALA was shown to 
inhibit Activin signalling (280). Furthermore, knockdown of Activin suppressed 
chondrogenesis, perhaps by regulating SOX9 (281,282). This is worth investigating and may 
implicate RALA as a new and important regulator of cartilage development.   
 
76 
 
5. In paper III, we provide evidence showing that in certain situations, RIG-I depends on 
liposomal delivery of RNA for activation. This has not been described before and could be 
an interesting topic of future investigations of RIG-I biology.  
 
6. Lipid-based transfection reagents mimic the properties of biological lipids to ensure fusion 
with cell membranes. Indeed biological lipids induce immune responses. The liposome-
induced immune response reported in paper III induced many of the same genes that are 
upregulated when biological lipids induce an immune response in arthrosclerosis. It is 
possible that these two immune responses occur through the same mechanisms. We have 
been funded by The Research Council of Norway to investigate this possibility over next 
three years. 
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Abstract 
Synthetic microRNAs regulate gene expression when transfected into cells, and may be 
used in strategies for molecular therapy both in vitro and in vivo. Liposomal transfection 
reagents are frequently used as delivery vehicles in both settings. Here we report on the 
immunological off-target effects observed following liposome transfection of synthetic 
microRNA-145 into human mesenchymal stem cells and human articular chondrocytes. The 
immune response was independent on endosome delivery and toll-like receptors but was 
mediated by RIG-I. Upregulation of immune genes required liposomal delivery, as no 
immune response was observed after electroporation of smiR-145 directly in to the cytosol, 
suggesting a new role of RIG-I. Immune response was seen both with blunt ended and 2-
nucleotide 3’ overhang versions of synthetic miR-145, and occurred in the absence of a 
5’ppp cap. Mutations in a centrally placed poly (UUUU) sequence reduced, but did not 
abolish the immune response. Interestingly, exposure to liposomes alone led to upregulation 
of several immune genes, including RIG-I mRNA. However, this process was not mediated 
by RIG-I. This insight is important for researchers to avoid unexpected results from gene 
transfer experiments in vitro and unwanted immune responses following the use of lipid-
based transfection reagents in vivo.
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Introduction 
MicroRNAs (miRNAs) are a class of small endogenous RNA molecules that regulate 
gene expression. miRNAs are initially transcribed as long primary transcripts called pri-
miRNAs. In the nucleus the pri-miRNAs are processed by the Drosha complex into 
precursor-miRNAs (pre-miRNAs). These are transported to the cytosol, where the Dicer 
complex cleaves the pre-miRNAs to yield mature and functional double stranded miRNAs 
approximately 21-22 nucleotides long. Usually, one of the strands is incorporated into the 
RNA-induced silencing complex (RISC) where it interacts with complementary sites in 
target mRNAs leading to either mRNA degradation or translational repression.(1,2) The end 
result will, in both cases, be reduced protein synthesis. However, miRNAs have also been 
shown to enhance protein synthesis.(3) To date the miRBase sequence database contains 2042 
mature human microRNA sequences. Each miRNA can regulate many genes, and it has 
recently been estimated that >60% of all human genes are regulated by miRNAs.(4) 
Transient transfection of synthetic microRNAs (smiRs) is often used in research 
protocols to investigate the function of miRNAs and genes. To yield specific and reliable 
results, these reagents must bind only to their designated RNA targets. However, liposome 
mediated transfection of siRNAs has been shown to induce off-target effects by upregulation 
of immune genes in different cell types.(5-8) This occurred through the sequence specific 
recognition of the siRNA by the endosomal RNA receptors toll-like receptor 3 (TLR3), 
TLR7 and TLR8.(7,9)  
We recently performed a study describing the changes in miRNA expression as human 
articular chondrocytes dedifferentiate during in vitro cell culture.(10) Here, miR-145 was 
found to be strongly upregulated in dedifferentiated chondrocytes. To identify miR-145 
targets and unravel molecular mechanisms of chondrocyte dedifferentiation we have 
subsequently performed liposome mediated transient transfection assays to overexpress miR-
145 in human articular chondrocytes (hAC) and human bone marrow-derived mesenchymal 
stem cells (hBM-MSCs). The present study describes our observation that lipid-mediated 
transfection of smiR-145 induced an immunological off-target effect in hBM-MSCs and 
hACs. Surprisingly, the immune response was independent of endosomal delivery and 
endosomal TLRs, but was mediated by the cytosolic viral sensor retinoic acid inducible–
gene 1 (RIG-I). The immune response was induced by smiR-145, but not by any of many 
other smiRs tested. smiR-145 sequences both with blunt ends and with 2 nucleotide 
overhangs induced immune response. The immune response was reduced following 
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mutations in a centrally placed UUUU sequence, but clearly depended also on other 
elements in the smiR-145 sequence. It required liposome delivery of smiR-145, as no 
immune gene changes were observed after delivery of smiR-145 directly into the cytosol 
using electroporation. This suggest a new role for RIG-I in certain situations, where RIG-I 
only recognize specific RNAs if it is delivered by liposomes. In fact, an immune response, 
albeit at lower level, was observed by exposing the cells to liposomes only. The liposome-
induced immune response was not mediated by RIG-I.  
Liposomal transfection reagents are frequently used as delivery vehicles in strategies for 
molecular therapy both in vitro and in vivo. Immunological off-target consequences of the 
use of liposomes and smiRs may confuse the interpretation of experiments, and potentially 
harm patients. Understanding the molecular mechanisms behind these effects and how to 
avoid them are therefore important if cell transfection is to be employed in clinical trials.  
These data may also open new lines of investigation into the understanding of RIG-I biology 
and perhaps also into the cellular immune responses to physiological lipids. 
 
Results 
Liposome mediated transfection of smiR-145 leads to upregulation of immune genes in 
mesenchymal stem cells 
Our initial studies showed that liposome mediated transfection of smiR-145 led to greatly 
increased upregulation of a number of immune genes. To formally demonstrate this, and to 
identify all the changes in gene expression following either liposome-mediated transfection 
or electroporation of smiR-145 relative to a negative control RNA sequence (smiR-neg), we 
performed global mRNA array analysis using hBM-MSCs from three donors.  
First, to evaluate our smiR transfection procedures, we established transfection of the 
positive control smiR-1, which is known to degrade PTK9 mRNA. As shown in 
Supplementary Figure S1, transient transfection using liposomes (Lipofectamine 2000) and 
electroporation (Amaxa nucleofection) resulted in 80-85% and 55-60% knockdown 
compared to smiR-neg, respectively. Following liposome mediated transfection of smiR-145 
into BM-MSCs, a total of 490 genes were upregulated and 209 genes were downregulated 
compared to the smiR-neg (Supplementary Table S2). The majority of the upregulated genes 
were associated with the immune system as shown by Gene Ontology (GO) analysis 
(Supplementary Table S3). Most significant, perhaps, was the strong upregulation of INFB1. 
Several of the upregulated genes are known to be involved in the regulation of IFNB1 
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expression, such as TLR3, MYD88, DDX58 (also known as RIG-1), IFIH1 (also known as 
melanoma associated gene 5, MDA5) and the transcription factor IRF7 (interferon regulatory 
factor 7).(11) IRF3, the gene coding for one of the other important transcription factors 
involved in the activation of interferon β (IFNB) was not upregulated. However, RT-qPCR 
showed that IRF3 was expressed at relatively high levels in these cells, while IRF7 mRNA 
was expressed at low to moderate levels but increased following liposomal transfection of 
smiR-145, confirming the microarray data (Supplementary Figure S2). Liposomes alone 
(Mock) or liposomes with smiR-neg induced low level upregulation of IRF7. Downstream of 
the interaction of IFNB with its receptor, several STAT genes which were found to be 
upregulated in this experiment are known to induce upregulation of proinflammatory, 
apoptotic and antiviral genes.(12) Many of the upregulated genes encode products which act 
as chemoattractants and stimulants for immune cells such as monocytes, T cells and B cells 
(e.g. CXCL10, CXCL11, CCL5, TNFSF13B, CCL8, CCL2, BST2), others are known to have 
roles in virus resistance (e.g. OAS1 OAS2 , OAS3, OASL,  RSAD2, MX1), while yet others 
are pro-apoptotic (e.g.TNFSF10, IFIT2).  A complete list of upregulated genes is presented 
in Supplementary Table S2.  
The downregulated genes were a much more heterogeneous group, and were changed 
less dramatically than the upregulated genes. Most of the downregulated genes encode 
proteins with roles in cell metabolism. A surprising proportion was pseudogenes or non-
protein coding genes. Some of the downregluated genes, such as RPS23, RPL10A, RPL15, 
RPL23 and RPLP0 are associated with ribosomes and translational elongation. Bioinformatic 
analysis using the miRWalk database predicted 14 % of the downregulated genes after 
liposomal transfection to be targets of smiR-145 (data not shown). Following transient 
transfection of smiR-145 using electroporation one gene was upregulated and nine were 
downregulated (Supplementary Table S4a). All the downregulated genes, except for the two 
ORFs, were also downregulated to the same levels in the liposomal smiR-145 transfected 
cells (Supplementary Table S4b) and have been shown to decrease after transfection with 
miR-145 mimics also in other studies.(13-15)  miRwalk predicted seven of  the nine genes 
(78%) to be miR-145 targets (data not shown). However, the number of miR targets 
suggested by downregulated genes following electroporation of miR-145 is likely to be 
falsely low in these cells, because the endogenous miR-145 level in hBM-MSCs was very 
high, and comparable to the highly abundant spliceosomal U6 snRNA (Supplementary 
Figure S3). This suggests that endogenous miR-145 had already downregulated its targets, 
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and that further overexpression by transient transfection of smiR-145 occurred in cells with 
few available miR-145 targets left.  
 
Immune genes are upregulated by liposomes alone and further upregulated by smiR-145  
To validate some of the upregulated genes from the microarray analysis by RT-qPCR 
analysis we chose CXCL10, CCL5, OAS2 and TLR3. Assaying the same genes to determine 
the sequence specificity of this response we transfected other small RNAs: smiR-140, anti-
miR-negative control (anti-neg), anti-145 and anti-140 in the same experiment. The results 
are shown in Figure 1a. For all the immune genes, liposome mediated smiR-145 transfection 
demonstrated greatly upregulated mRNA levels compared with untransfected controls. The 
levels of CCL5 and CXCL10 following transfection of all the RNA sequences by 
electroporation were similar to the untransfected controls. For liposome mediated 
transfection, none of the RNA sequences other than smiR-145 gave values above mock and 
smiR-neg transfection. However, for all the liposome mediated transfections, the levels of 
the immune genes were consistently higher than the levels obtained for electroporation, and 
those observed in untransfected controls.  This shows that liposomes alone induced 
upregulation of immune genes. Using hACs we obtained the same results after transfection 
of mock, smiR-neg and smiR-145 (Figure 1b). The upregulation of CCL5 and CXCL10 
following liposome mock transfection and transfection of smiR-neg and smiR-145 was 
confirmed at the protein level both in hBM-MSC and in hAC (Figure 2a, b). As part of 
another experiment, using cells from another donor, five more smiRs were used for liposome 
mediated transfection. Again, only smiR-145 increased CCL5 and CXCL10 levels above 
levels observed by mock transfection, further supporting specificity for smiR-145 for the 
immune gene upregulation (Supplementary Figure S4a, b). Supplementary Figures S4c and d 
show that there was a dose-response relationship for the liposome mediated immune 
response, and Supplementary Figures S4e, f and g show a similar dose-response relationship 
and kinetics for the smiR-145 induced immune response.  
As shown in Supplementary Figure S1, we obtained better reduction of the miR-1 target 
gene PTK9 for liposome mediated transfection than for electroporation. This could lead to 
the suspicion that the efficacy of the transfection was not sufficiently high to induce immune 
response when the smiRs were introduced by electroporation. From the liposome 
transfection dose-response experiments, using 25 nM of smiR-145, the immune genes were 
still greatly upregulated (Supplementary Figure S4e, f). In parallell experiments using 25 nM 
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of smiR-1 we saw approximately 60% knockdown of PTK9, which was exactly the same 
knockdown as that observed using electroporation (Supplementary Figure S5). This shows 
that the failure to obtain equal knock-down levels was not the reason why no immune 
response was observed when using electroporation of smiR-145. 
 
To exclude the possibility that the liposome mediated immune response was restricted to 
Lipofectamine liposomes, we also tested siPORT NeoFX, which is also a cationic liposomal 
transfection reagent. siPORT NeoFX was not as efficient as Lipofectamine as determined by 
PTK9 levels after transfection with smiR-1 (Supplementary Figure S6a). However, siPORT 
NeoFX reagent alone also increased CXCL10 and CCL5 mRNA levels, and a further 
increase was observed after transfection of smiR-145 (Supplementary Figure S6b,c). 
 
smiRs are not taken up into endosomes, and the immune response is not induced by 
toll-like receptors 
Endosomal toll-like receptors (TLRs) have been shown to be responsible for immune 
response against siRNAs after liposomal transfections.(7,9,16) Therefore, it has been thought 
that siRNAs transfected using liposomes are taken up by the endosomal pathway before 
being released into the cytosol. In the endosomes, TLR3 binds double-stranded RNA 
(dsRNA) and subsequently signal through the adaptor protein TRIF, while TLR7 and 8 bind 
single-stranded RNA (ssRNA) and signal through MYD88.(17,18) Our microarray analyses 
showed upregulation of both TLR3 and MYD88 mRNA following liposome mediated smiR-
145 transfection, but TLR7 and TLR8 was not expressed in these cells (GEO database, 
accession number GSE40387). Suspecting that the immune response could be mediated 
through one of these pathways, we sought evidence for this by independently knocking 
down TLR3 and MYD88 by electroporation of siRNAs two days prior to liposomal smiR-145 
transfection. CXCL10 and CCL5 mRNA expression was again chosen as readout. However, 
highly efficient knockdown of TLR3 and MYD88, did not decrease CCL5 or CXCL10 levels 
after liposomal smiR-145 transfection as would be expected if these were the pathways 
involved (Figure 3a, b). TLR3 is also expressed on the cell surface of certain cells. However, 
flow cytometry analysis showed that hBM-MSCs did not express TLR3 at the cell surface, 
and adding smiR-145 to the culture medium without liposomes did not lead to upregulation 
of either CCL5, CXCL10, OAS2 or TLR3 (data not shown). Also, two donors were treated 
with a MYD88 homodimerization inhibitory peptide before liposomal transfection of smiR-
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145 and subjected to microarray and RT-qPCR analysis. No inhibitory effect on the immune 
response was observed compared to cells treated with a control peptide (data not shown). 
This strongly indicated that endosomal TLRs were not responsible for the immune response. 
To further explore this issue, we took advantage of the fact that endosomal TLRs depend on 
endosomal acidification for signaling.(19) Using chloroquine to inhibit endosomal 
acidification, we again observed highly upregulated levels of CCL5 and CXCL10 mRNA 
following liposomal smiR-145 transfection, and these levels were unaffected by chloroquine 
treatment (Figure 3c). Based on these results we wanted to see if the liposomes containing 
smiRs were taken up by the endosomal pathway at all. To this end we performed liposome 
transfection of a FAM-labeled smiR into hBM-MSCs. Using antibodies against the early 
endosome marker EEA1, the late endosome marker CD63 and the lysosome marker LAMP1, 
confocal microscopy was used to examine for co-localization following smiR transfection. 
Representative images are shown in Figure 4. Most liposomes seemed to stick together to 
form large aggregates, and these were not co-localized with EEA1, CD63 or LAMP1 
staining vesicles. Co-localization with CD63 could be observed for very small smiR-FAM 
vesicles 45 minutes after transfection in one cell out of 19 observed, but this was never seen 
for EEA1 or LAMP1 (Figure 4). Combined, these experiments showed that the smiR-145 
mediated immune response was independent of TLRs, and that the main uptake of liposome 
transfected smiRs did not involve the endosomal pathway. It is worth mentioning that none 
of the siRNAs used in this study induced an immune response after electroporation as 
determined by CCL5 and CXCL10 expression (data not shown). 
 
smiR-145 induced immune response is mediated through RIG-I 
As endosomal receptors could be excluded as being responsible for the smiR-145 
induced immune response, our attention focused on cytosolic RNA receptors. mRNA levels 
for the cytosolic RNA binding receptors PKR (official gene symbol - EIF2AK2) and RIG-I 
(DDX58) were increased 3.9 and 18.1 fold, respectively, in our microarray analysis after 
liposomal smiR-145 transfection (Supplementary Table S2). However, delivery of smiR-145 
directly into the cytosol by electroporation did not lead to upregulation of immune genes, 
suggesting that these cytosolic receptors were unlikely to be involved in the immune 
activation. Nevertheless, we still thought it could be possible that PKR or RIG-I, by an 
unknown mechanism, could be involved in the immune gene upregulation observed after 
liposomal smiR-145 transfection. Therefore, we first validated the increased PKR and RIG-I 
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expression in these donors. Both were found to be upregulated by liposomes alone (mock), 
and further upregulated by smiR-145 (Figure 5a, b). Then, we separately knocked down PKR 
and RIG-I before liposomal smiR-145 transfection. PKR knockdown did not affect the 
highly upregulated levels of CCL5 or CXCL10 resulting from the smiR-145 transfection 
(Figure 5c). RIG-I siRNA transfection resulted in 55-60% knockdown of RIG-I mRNA 
before smiR-145 transfection. After smiR-145 transfection CCL5 and CXCL10 mRNA levels 
were reduced by ~75-95% compared to scrambled control siRNA. Results from RIG-I 
knockdown were consistent in MSCs from 3 consecutive donors (Figure 5d). Protein levels 
of CCL5 and CXCL10 were measured in the supernatants from two of the donors and 
showed relative reductions after RIG knockdown similar to the mRNA levels (Figure 5e). 
Western blot analysis showed a band of approximately 101 kDa, which corresponds to the 
molecular weight (MW) of RIG-I, appearing 24 hours after smiR-145 transfection (Figure 
5f). This band was not detected in cells treated with RIG-I siRNA. Another band with a MW 
around 90-95 kDa was also visible on the membrane. However, as this band did not change 
upon smiR-145 stimulation or by RIG-I siRNA treatment, this is likely to be a non-specific 
band. To rule out the possibility that the results from the RIG-I knockdown might be due to 
off-target effects of the siRNA used we tested another siRNA against RIG-I in two of the 
donors. The results were the same, although less pronounced (Supplementary Figure S7). 
These results strongly point to RIG-I as the mediator of the smiR-145 induced immune 
response. 
 
smiR-145 induced immune response is mediated by RIG-I also in the HEK293 TN cell 
line 
RIG I contain two caspase recruitment domains (CARDs) at its N-terminal which are 
responsible for signaling and an RNA binding domain at the C-terminal.(20) To further 
investigate the role of RIG-I in the smiR-145 induced immune response we overexpressed 
full length RIG-I (RIG-I), RIG-I without CARD domains (RIG-IΔCARDs), only the CARD 
domains (RIG-I CARDs) and control vector (EGFP) in the 293TN cell line followed by 
liposomal transfection of smiR-145. RT-qPCR analysis showed low RIG-I levels in this cell 
line unaffected by mock, smiR-145 and plasmid control transfection using primers which 
amplify a region within the CARD1 and CARD2 domains (Figure 6a, Supplementary Figure 
S8a). High levels of RIG-I were detected in cells transfected with full-length RIG-I and RIG-
I-CARDs, but not after transfection with RIG-IΔCARDs (Figure 6a). Transfection of all 
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constructs resulted in cells expressing GFP and proteins of the correct size using antibodies 
specific for the C-terminus of RIG-I and GFP, respectively (Supplementary Figure S8b,c). 
Although low levels of RIG-I mRNA were detected in the 293TN cells, we did not detect 
endogenous RIG-I protein using western blot (Figure 6b, right lane). Overexpression of full-
length RIG-I in the 293TN cells showed a band corresponding to the MW of RIG-I (Figure 
6b, left lane). The lack of immune response in 293 TN cells, without prior overexpression of 
RIG-I, is consistent with previous findings where treatment of poly (I:C) did not induce 
immune response in 293T cells.(21)  Overexpression of full-length RIG-I induced CCL5 and 
CXCL10 in the absence of smiR-145, but increased further by smiR-145 transfection (Figure 
6c, d). The combination of full-length RIG-I and smiR-145 also induced CCL5 and CXCL10 
protein secretion (Figure 6e, f). Transfection of RIG-IΔCARDs or RIG-I CARDs did not 
induce an immune response, either alone or combined with smiR-145 transfection, 
demonstrating that full-length RIG-I, containing both the RNA recognition and signaling 
domains, was required for upregulation of immune genes. Co-transfection of full-length 
RIG-I and RIG-I siRNA, followed by liposomal smiR-145 transfection, led to decreased 
mRNA and protein levels of CCL5 and CXCL10 compared to co-transfection of full-length 
RIG-I and scrambled control siRNA (Figure 6g, h). We also wanted to transfect a Cy3 
labelled smiR-145 to evaluate possible co-localization with RIG-I/EGFP. However, the 
addition of Cy3 abolished the immune response completely in hBM-MSCs (data not shown). 
The labeling procedure leads to Cy3 attachment to both strands, but is not meant to affect the 
binding of smiR to its target mRNA. Presumably smiR-145 binding to RIG-I involves other 
parts of the smiR-145 molecule, and this interaction seems to be affected by Cy3 labeling. 
 
Structure and sequence of smiR-145 of importance for immune gene upregulation 
We have considered the possibility that technical aspects could explain some of our 
observations. However, in all these experiments five different batches of smiR-145 from 
Ambion were used, which makes it unlikely for “batch contamination” to be responsible for 
the immune response. smiR molecules produced by Ambion are double-stranded, 21-23 nt 
long with sequences identical to the sequence of the mature endogenous miRNA. The 
opposite strand is 100% complementary to the mature sequence. However, smiR molecules 
from Ambion have an unknown proprietary chemical modification, and have 2-nucleotide 
3’overhang at each end which could possibly influence the immune response. In addition, 
the Ambion smiR molecules do not have a 5’triphosphate (5’ppp) which has been shown to 
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be important for RIG-I activation in several studies.(22-24)  In contrast, smiRs from Qiagen do 
not contain any chemical modifications or overhangs (Supplementary Figure S9a). To 
determine the possible role played by the chemical modification and 3’ overhangs, smiR-145 
from Ambion and Qiagen were liposome transfected into MSCs in parallel. Figure 7a shows 
that smiR-145 from Qiagen (smiR-145-Q) induced CCL5 and CXCL10 to the same levels as 
smiR-145 from Ambion (smiR-145-A). The lack of immune response against smiR-1-Q 
confirms that the immune response was specific and not due to a general response to the 
Qiagen miRNA mimics. smiR-1-Q was also used in the positive control experiment for 
transfection efficiency (Supplementary Figure S9b).   
Next we considered sequences within smiR-145 which might be important for the 
immune gene upregulation. The sequence 5’-GUCC-3’ has been shown to be a potent 
immunostimulatory motif mediated by TLR7 (The United States Patent and Trademark 
Office (uspto.gov), Pat no: 8,076,068).(5) Both miR-145 and miR-642a contain this 4mer 
sequence (Supplementary Table S5). However, transfection of smiR-642a did not induce an 
immune response in hBM-MSCs (Figure 7b). Aligning the mature miR-145 sequence with 
sequences of dsRNA viruses (the RNA virus database) showed that several viruses contained 
the 5’UCCCAGG-3’ sequence found within miR-145. miR-331 also contain this sequence 
(Supplementary Table S5). We then transfected smiR-331, but no immune response was 
observed (Figure 7b). Poly (U) sequences are known to activate RIG-I.(25) Both miR-145 and 
miR-140-5p contain a poly (UUUU) sequence in the same position in the mature sequence 
(Supplementary Table S5), but smiR-140 also did not lead to immune gene upregulation in 
our experiments (Figure 1a). In order to further explore the role of the poly (UUUU) 
sequence for smir-145 induction of immune genes we transfected two custom made 
sequences from Qiagen, one where the poly (UUUU) was changed into (UCCU) (smiR-145 
2mut) and the other into poly (CCCC) (smiR-145 4mut). Figure 7c shows that smiR-145 
2mut decreased CCL5 and CXCL10 by 50-60%, while smiR-145 4mut decreased the levels 
to 70-80% compared with the non-mutated smiR-145-Q. However, the immune response 
was not abolished by these mutations as the immune gene upregulation induced by smiR-145 
4mut was still more than hundred times higher than mock and smiR-neg-Q transfections 
(Figure 7c). Still, the poly (UUUU) sequence is clearly important for smiR-145 binding to 
RIG-I, presumably combined with other parts of the smiR-145 sequence and possibly also 
the smiR-145 three-dimensional structure. 
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The liposome-induced immune response is not mediated by RIG-I 
Several of the experiments described above showed that exposure to liposomes alone led 
to upregulation of immune genes. Our microarray analysis, on which the detection of 
upregulated immune genes, compared smiR-neg and smiR-145. Genes upregulated by 
liposomes alone and not further upregulated by smiR-145 would not be detected by the 
microarray analysis. We suspected that this might be the case for several important pro-
inflammatory cytokines such as interleukin 6 (IL6), IL8 and IL1B, shown by others to be 
upregulated following liposome mediated transfection of siRNA,(7) but not differently 
expressed in our microarray data. We therefore decided to analyse these genes by RT-qPCR 
in untransfected cells, cells exposed to liposomes alone (mock), liposomes plus smiR-neg 
and liposomes plus smiR-145. Figure 8a shows that these genes were upregulated in all the 
cells exposed to liposomes, but that they were not further upregulated by smiR-145. IL8 
protein concentration in the culture medium followed the same pattern as the mRNA levels 
(Figure 8b). Further, we wanted to see if this immune response was also mediated by RIG-I. 
In three donors we knocked down RIG-I with siRNA before exposing the cells to liposomes. 
This did not lead to decreased levels of CCL5, CXCL10, IL6, IL8 or IL1B after liposome 
exposure, demonstrating that the liposome induced immune response was not mediated by 
RIG-I (Figure 8c). Presumably the other genes shown to be upregulated by liposomes, i.e. 
RIG-I itself, TLR3, OAS2, PKR and IRF7 are upregulated by the same mechanism. 
 
Discussion 
smiRs and and miRNA inhibitors hold great potential as therapeutic agents and are also 
important tools for identification of miRNA targets and their role in biological processes. A 
very common method for delivery of these molecules into cells is the use of liposome-based 
transfection reagents. Here we show that liposome-mediated transfection of smiR-145 
induced upregulation of a substantial number of immune genes and the translation of their 
corresponding proteins in hBM-MSCs and hACs. The immune response was dependent on 
the liposomes, as no immune response was observed after electroporation of smiR-145. 
Surprisingly, the immune response was independent of uptake through endosomes and 
signaling through TLRs. Knockdown experiments demonstrated that the immune response 
was mediated by RIG-I. Interestingly, liposomes alone also induced a moderate immune 
gene up regulation, but this immune response was not mediated by RIG-I. 
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Exposure to exogenous RNA most commonly represents danger, and the cell has several 
strategies to evaluate the danger and deal with it. Many RNA viruses will be taken up into 
endosomes, where the viral dsRNAs are recognized by TLR3, and ssRNAs are recognized 
by TLR7 and TLR8. The TLRs will induce upregulation of immune genes to ensure the 
demise of the infecting virus. In the cytoplasm, short dsRNAs may be bound by PKR and 
OAS1-3.(26) PKR binding will induce an immune response or inhibit protein synthesis, while 
binding to members of the OAS family will predominantly lead to RNA degradation. Also in 
the cytoplasm, blunt-ended dsRNA may bind to RIG-I, MDA5 or LPG2. LPG2 lacks 
CARDs and thus cannot induce signalling, but may act as a negative regulator of RIG-I.(27) 
MDA5 binds long dsRNA (1-10 kb in length)(28) leading to upregulation of immune genes. 
RIG-I binds short dsRNA also leading to an antiviral response. mRNAs encoding the 
dsRNA endosomal receptor TLR3 and the adaptor protein MYD88 involved in TLR7 and 
TLR8 signaling were both upregulated in this study. However, TLRs were found not to be 
involved in the smiR-145 induced immune response based on the observations that 
fluorescent smiR did not co-localize with early or late endosomal markers, and the immune 
response was not abolished by inhibition of endosomal acidification or efficient knock-down 
of TLR3 and MYD88. Also TLR7 and TLR8 were not expressed by these cells. Previous 
studies suggest that immunological off-target effects depend on cell type, delivery method 
and RNA sequence. While Sioud observed inhibition of liposomal siRNA-induced TNFα 
and IFNα production in adherent human peripheral blood mononuclear cells following 
chloroquine treatment, and a complete abrogation after electroporation of the same siRNA 
directly into the cytosol, suggesting an endosomal pathway, (7) Hornung et al. observed IFNα 
production following electroporation of siRNA into the cytosol of plasmacytoid dendritic 
cells.(5) As is the case for the innate immune response induced upon infection with certain 
RNA viruses, the pathway used by siRNAs and smiRs may vary between cell types.(11)  
The fact that liposome mediated transfection was required, while electroporation of 
smiR-145 directly into the cytosol did not induce an immune response pointed away from 
RNA receptors in the cytosol. However, as TLRs could be excluded and the cytosolic 
receptors were actually upregulated after liposomal transfection of smiR-145, we decided to 
perform experiments to see if they could be involved. Of the cytosolic RNA receptors, PKR 
was excluded based on the observation that siRNA knockdown of PKR did not affect the 
immune response. MDA5 was considered unlikely because it is known to bind only long 
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dsRNAs. Upon siRNA inhibition of RIG-I, however, CCL5 and CXCL10 mRNA and 
protein was reduced compared to scrambled control siRNA. The identification of RIG-I as 
the receptor responsible for the smiR-induced immune response was further supported by 
experiments in the HEK293 TN cell line.  
To explain exactly how liposome mediated transfection of smiR-145 led to miRINIR we 
need to reconcile the following observations: i) Liposomes alone induced an immune 
response that was different from that induced by smiR-145 transfection, but included 
upregulation of RIG-I mRNA. ii) RIG-I protein was detectable at 24 hours in cells exposed 
to liposomes plus smiR-145. The upregulation of RIG-I protein, and the miRINIR, was 
inhibited by RIG-I siRNA. iii) Electroporation of smiR-145 did not induce an immune 
response in these experiments. In this discussion, for physiological relevance, we speculate 
about similarities between the cellular responses to liposome/smiR-145 particles and RNA 
viruses.  
First, the immune response to liposomes was RIG-I independent, but induced 
upregulation of RIG-I and a number of other immune genes. Others have also shown that 
liposomes can induce an innate immune response in exposed cells.(29) Recently, it was shown 
that fusion of virus envelopes or lipofectamine with cell membranes induced an immune 
response that was dependent on STING, a transmembrane protein in the endoplasmic 
reticulum, but the mechanism leading to the immune response was not revealed.(30) Similar 
to these studies we have not, determined exactly how liposomes induce an immune response. 
However, there are several possible lipid receptors in the cell membrane, some of which are 
known to induce upregulation of immune associated genes.(31,32) Also, many viruses enter 
cells through fusion with the plasma membrane. The actin cytoskeleton beneath the plasma 
membrane acts like a barrier for pathogens and is disassembled during virus entry.(33,34) 
Disassembly of the actin cytoskeleton has been shown to induce upregulation of immune 
genes.(35,36) This is the first level of immune response against enveloped viruses, and a 
similar mechanism may explain the liposome-mediated immune response reported here.  
Second, the smiR-145 induced immune response was dependent on RIG-I. RIG-I is 
constitutively expressed in mouse embryonic fibroblasts,(37) and is frequently cited as being 
constitutively expressed also in human cells, albeit at low levels. In untransfected hBM-
MSCs we observed very low level expression of RIG-I mRNA as determined by RT-qPCR. 
The RIG-I protein was only detectable 24 hours post-transfection.  It has been shown that 
RIG-I is associated with the actin cytoskeleton beneath the plasma membrane.(38,39) If RIG-I 
 15 
 
is sequestered to immediately below the plasma membrane, it may still be present in 
untransfected cells at functional concentrations although it was undetectable using our WB 
settings. Also, constitutively expressed RIG-I is normally found in a closed, non-responsive 
configuration.(40) It is conceivable that distortion and polymerization of the actin 
cytoskeleton, possibly brought about by fusion of liposomes with the plasma membrane or, 
in vivo, by fusion of the virus envelope with the plasma membrane, may activate RIG-I to 
enable binding to smiR-145 or virus dsRNA. Interestingly, RIG-I has been shown to directly 
interact with actin and also to regulate actin polymerization.(38) 
Third, electroporation of smiR-145 did not bring about an immune response, despite 
small amounts of RIG-I protein presumably being present in the cells. One explanation for 
this may be the one described above, that the RIG-I is present only in the closed, non-
responsive form and that electroporation does not affect the cells in a way that activates 
RIG-I.  Another possibility is that RIG-I is sequestered immediately under the plasma 
membrane to such an extent that it is not available to bind smiR-145 introduced deeper 
within the cytoplasm by electroporation. This makes sense because it would be much more 
efficient for RIG-I to survey the actual pathways viruses utilize for cell entry instead of 
keeping the whole cytosol under surveillance. To the best of our knowledge, the dependency 
of liposome delivery for RIG-I activation has not been described before and open new lines 
of investigation into RIG-I biology. However, this phenomenon may differ between cell 
types and the RNA used for transfection. 
In summary, then, our hypothesis is that liposomes fuse with the plasma membrane, 
which may trigger membrane-associated lipid receptors and/or distort the actin cytoskeleton 
which in turn upregulates immune genes. Further, we hypothesize that the smiR-145 induced 
immune response is separate from the immune response induced by liposomes alone, and is 
driven by the RIG-I RNA receptor.  RIG-I may be sequestered immediately below the 
plasma membrane, in physical contact with actin as shown previously,(38,39) and smiR-145 
activation of RIG-I sets off an immune response which in turn further upregulates RIG-I in a 
positive feedback loop. 
The ligand for RIG-I in our study was smiR-145, and not any of another 11 smiRs and 
anti-miRs tested. This suggests that there is likely a restricted number of smiRs suitable as 
ligands in this system. Generally, short RNAs rich in GU or poly(U) motifs have been shown 
to be more likely to induce immune responses via RIG-I.(25) As such, it may not be 
surprising that the miR-145 sequence (5’-GUCCAGUUUUCCCAGGAAUCCCU-3’) was 
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found to induce an immune response. Using other smiRs with sequence similarities that 
covered almost the entire smiR-145 sequence we were unable to identify short smiR-145 
sequences which affected the RIG-I mediated immune response. However, by mutating the 
poly (UUUU) within the smiR-145 sequence we showed that this sequence is involved in the 
immune response. Still, a strong immune response was found even when the entire poly 
(UUUU) sequence was mutated, showing that also other parts of the smiR-145 sequence or 
three-dimensional structure are important for the immune gene upregulation.  
 RIG-I has been described to bind short blunt ended uncapped dsRNA, preferably with 
5’ppp groups, but RIG-I has also been shown to bind dsRNA without 5’ppp and ssRNA 
containg 5’ppp.(21-24) The lack of cap is typical of viral sequences, and allows RIG-I to 
discriminate between self and viral dsRNAs.(41) Naturally occurring miRNAs processed by 
the Dicer complex have 2-nucleotide 3’ overhangs. These overhangs impair the unwinding 
of the dsRNA substrate and inhibit immune gene induction through RIG-I, thus introducing 
another mechanism by which the cell can discriminate between self and nonself dsRNAs.(21) 
However, it has been shown that RIG-I are activated by RNA molecules containing 
overhangs.(42) In contrast to these previous findings, overhangs did not impact on the smiR-
145 induced immune response in our experiments. This may be explained by use of different 
cells or by the inherent immunostimulatory properties within the different RNA sequences. It 
is possible that some RNA sequences are recognized by their ends, while others are 
recognized based on internal sequences or by secondary or tertiary structures that are not 
influenced by the end structures. Finally, a study by Witwer et al. demonstrated that a smiR 
mixture containing miR-145 reduced poly I:C induced IFN-β protein synthesis in macaque 
machrophages.(43) However, in contrast to the other smiRs in the mixture smiR-145 was not 
definitely shown to bind target sequences in the IFNB 3’UTR. Also, the possibility that 
liposome mediated transfection of smiR-145 alone might upregulate immune genes in these 
cells was not investigated – the immune response observed was entirely explained by the 
poly I:C treatment. Thus, if there are real discrepancies between the observations published 
in this study and those described here, they are likely to be due to technical differences and 
the use of different cells from different species. 
The results described in this paper provide important information for researchers using 
different transfection techniques. Clearly an immune response can potentially mask or 
change the cellular response to the synthetic miRNA used, making it very difficult to 
interpret the actual role of the miRNA under investigation. Another concern is the unwanted 
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immune gene upregulation which may occur following liposome mediated transfection of 
smiRs in vivo. However, the induction and magnitude of the immune response may depend 
on cell type, transfection method and the reagents used.(44,45) As shown here, for hMSCs and 
hACs electroporation of smiRs is the in vitro transfection method of choice to avoid off-
target immune responses. For researchers using other cells the recently established RNA 
immuno database provides an opportunity to analyse and compare the results of studies 
using RNA inhibition techniques,(46) and may be used as a guide to avoid or minimize 
immunological off-target effects in transfection experiments.  
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Materials and methods 
Chemicals and reagents 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise 
stated. Information about Taqman assays, smiRs and Anti-miRs, siRNAs, antibodies and 
singleplex arrays are listed in Supplementary Table S1. 
 
Isolation and culture of cells 
hBM-MSCs and hACs were isolated and cultured as previously described.(10,47) The 
hBM-MSCs fulfilled the criteria for definition of MSCs as proposed by the Mesenchymal 
and Tissue Stem Cell Committee of the International Society for Cellular Therapy.(48) All 
donors provided written, informed consent. The study was approved by the Regional 
Committee for Medical Research Ethics, Southern Norway, Section A. From the day of 
isolation until the first passage cells were expanded in DMEM/F12 (Gibco, Paisley, UK) 
supplemented with 20% FBS (Cambrex, East Rutherford, NJ), 100 units/ml penicillin, 100 
μg/ml streptomycin and 2.5 μg/ml amphotericin B. The AC culture medium also contained 
50μg/ml ascorbic acid. Culture medium was changed every 3-4 days. After the first passage 
amphotericin B was removed and 10% FBS, instead of 20%, was used. At 50-60% 
confluence cells were detached with trypsin-EDTA and seeded into new culture flasks. For 
hBM-MSCs, 12 different donors were used for consecutive experiments. All experiments 
were performed on cells between passage 3 and 6, in log phase of growth. For AC the 
experiments were performed on cells from two donors at passage 3 and 4. HEK293 TN cells 
(System Biosciences, CA) were cultured in DMEM/F12 - high glucose (Gibco) 
supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin.  
 
Plasmids  
RIG-I constructs (all fused with GFP) were kindly provided by Carolyn B. Coyne 
(University of Pittsburgh, Department of Microbiology and Molecular Genetics). The EGFP-
RIG-I plasmid codes for full-length RIG-I (aa1-925) with GFP fused at its N terminus.(39) 
The EGFP-RIG-IΔCARDS construct (aa201-925) does not contain the CARD1 and CARD2 
domains necessary for CARD-CARD interaction with the downstream adaptor protein 
MAVS and subsequent signalling. However, it contains the HELICASE domain responsible 
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for RNA recognition and helicase activity. The EGFP-RIG-I CARDS construct (aa1-225) 
contains CARD1 and CARD2, but not the HELICASE domain. The control construct EGFP 
only contains EGFP. 
 
Transfection 
Lipofectamine 2000 was used for liposomal transfection according to the reverse 
transfection protocol from the manufacturer (Invitrogen, Carlsbad, CA). Briefly, for each 
reaction 500.000 cells were transfected using 50 nM smiRs (double-stranded RNA) or anti-
mirs (single-stranded RNA) (Ambion, Austin, TX) and 8 ul Lipofectamine 2000, and were 
seeded in a total volume of 2.5 ml culture medium without antibiotics. Other concentrations 
of smiRs and Lipofectamine 2000 were used for dose-response experiments as stated in the 
figures. siPORT NeoFX transfection reagent (Ambion) was used in one experiment. 
HEK293 cells were transfected according to the forward transfection protocol (Invitrogen) 
using 300.000 cells, 8 Pl Lipofectamine 2000, 500 ng plasmid DNA, 50 nM smiRs with or 
without 150 nM siRNA in a total volume of 2.5 ml. 
The Amaxa Nucleofection system was used according to the protocols from the 
manufacturer (Lonza, Walkersville, MD) (http://www.lonzabio.com/technology.html). For 
both hBM-MSCs and hACs the Human Chondrocyte Nucleofector Kit and the U-23 
program was used as these conditions were shown in pilot experiments to give the best 
transfection efficiency for both cell types. Briefly, 1 x106 cells were used for each 
nucleofection reaction using 3 μM smiRs or anti-miRs in a total volume of 100 μl 
nucleofector solution. Directly after transfection the cells were seeded in culture medium 
without antibiotics containing 20% FBS. Transfection of siRNAs was performed with the 
Amaxa nucleofection system at a final concentration of 1.5 μM for each siRNA two days 
prior to liposomal transfection.  
For inhibition of endosomal acidification, chloroquine (InvivoGen, San Diego, CA) was 
added to the culture medium at 0, 0.1, 1, 10, 50, 100 or 500 μM 2 hours prior to transfection 
and was also included in the culture medium during transfection. 
For all transfections the culture medium was changed into regular culture medium 
without antibiotics 20-24 hours after transfection, and samples were harvested for analysis 2 
days post transfection unless otherwise stated.  
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Inhibition of MYD88 
MYD88 signaling was blocked by incubating hBM-MSCs with a MYD88 inhibitory 
peptide and a control peptide following protocols in the MyD88 Homodimerization 
Inhibitory Peptide Set (Imgenex, San Diego, CA). 
 
mRNA and miRNA quantification – RT-qPCR 
Total RNA for mRNA analysis was isolated using the RNAqueous Micro Kit following 
protocols from the manufacturer (Ambion). Following DNase treatment (Ambion), RNA 
was quantified by spectrophotometry (Nanodrop, Wilmington, DE). From each sample 200 
ng total RNA was reverse transcribed into cDNA (total volume of 20μl) by using the High 
Capacity cDNA Reverse Transcription kit following protocols from the manufacturer 
(Applied Biosystems, Abingdon, U.K.). RT-qPCR was performed using Taqman® Gene 
Expression assays and Taqman Universal PCR master mix (Applied Biosystems) with the 
7300 Real-Time RT PCR system (Applied Biosystems) following protocols from the 
manufacturer. All samples were run in technical triplicates. Each replicate contained 1.0 μl 
cDNA in a total volume of 25 μl. The thermocycling parameters were 95ºC for 10 minutes 
followed by 40 cycles of 95ºC for 15 seconds and 60ºC for 1 minute. GAPDH was used as 
endogenous control as its expression was not affected by transfection.  
Total RNA enriched with small RNA molecules (including miRNA) was isolated using 
the miRNeasy Mini Kit (Qiagen, by, land) following protocols from the manufacturer. 
Following DNase treatment, the total RNA was quantified by spectrophotometry. Reverse 
transcription was performed using 10 ng total RNA (total volume of 15μl) and primers 
included in the Taqman® microRNA assays (Table 1) (Applied Biosystems). For RT-qPCR 
Taqman® MicroRNA Expression assays (Table 1) the Taqman Universal PCR master mix 
was used, and all samples were run in technical triplicates. Each replicate contained 1.33 μl 
cDNA in a total volume of 20 μl. The same thermocycling parameters as described above 
were used. U6 was used as endogenous control.  
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Microarray analysis 
Microarray analysis was performed at the Norwegian Microarray Consortium. Nanodrop 
(Wilmington, DE) and Bioanalyzer (Agilent, Santa Clara, CA) was used to check the 
concentration and integrity of the samples, respectively. For each sample 500 ng total RNA 
was amplified and labeled with biotin using Illumina® TotalPrep RNA Amplification Kit 
(Ambion). The biotin labeled cRNA (750 ng) was hybridized onto Illumina’s HumanHT-12 
v4 Expression BeadChip and subsequently stained with streptavidin-Cy3. The chips were 
then scanned using Illumina® BeadArray™ Reader. Results were imported into Illumina 
GenomeStudio v. 2010.2 Gene Expression v. 1.7.0. for data extraction and initial quality 
control. Further quality control was performed with the microarray analysis software J-
Express(49) and included  log(2) transformation, quantile normalization, box plot analysis, 
correspondence analysis and hierarchical clustering. Differential expression between 
samples was calculated using Rank product (RP).(50) A threshold of 2-fold and q-value <0.05 
(adjusted p-value) was used to generate lists with differently expressed genes. Gene 
Ontology (GO) overrepresentation analysis (Bonferroni correction, p <0.05) was performed 
on the gene lists from the RP-analysis. The guidelines from the “Minimal Information About 
a Microarray Experiment” (MIAME guidelines) were followed and the microarray data are 
available in the GEO database with accession number GSE40387. 
 
Bioinformatic analysis 
The miRWalk prediction database was used to predict miR-145 binding sites in the 
3’UTR of the downregulated genes from the microarray analysis. Comparative analysis was 
performed by 6 prediction programs (miRanda, PICTAR5, miRDB, PITA, miRWalk and 
TargetScan). A positive prediction in 4 out of the 6 programs was chosen as criteria for 
being counted as a true prediction. 
 
Cytokine measurements 
The concentration of secreted CCL5 and CXCL10 in the culture medium was determined 
using singleplex assays from Biorad (Biorad, Hercules, CA) and the Luminex system 
(Luminex, Austin, TX) following protocols from the manufacturer. 
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Western blotting 
Cell lysates corresponding to 200.000 cells were loaded onto an 8% polyacrylamide gel 
and transferred to PVDF membranes. After 1h blocking in 5% milk the membrane was 
incubated overnight with antibodies against RIG-I followed by washing and incubation with 
horse radish peroxidase conjugated secondary antibodies. The Precision Plus Protein All 
Blue Standards was used to determine molecular weights (Biorad). Pierce ECL western 
blotting substrate solution (Thermo Scientific, Runcorn, UK) was used for development and 
pictures were captured using the Carestream Image Station 4000 R Pro and the Carestream 
MI software (Carestream, Rochester, NY). The membrane was washed and reprobed with 
antibodies against β-actin (Abcam, Cambridge, UK) which was used as loading control.  
 
Confocal microscopy 
To determine if liposomes containing smiRs were delivered to the endosomal pathway, 
hBM-MSCs were transfected with a FAM-labeled smiR. At indicated time points cells were 
fixed with 4% paraformaldehyde for 15 min and then permeabilised with 0.1% Triton X-100 
for 30 min. After washing, cells were incubated with primary antibodies against EEA1, 
CD63 and LAMP-1 for 1h at room temperature, washed again, incubated with secondary 
antibody for 30 min at room temperature, washed and mounted with ProLong Gold antifade 
reagent with DAPI (Invitrogen). Primary antibodies were kindly provided by Anne 
Simonsen (University of Oslo, Department of Medical Biochemsistry, Institute of Basic 
Medical Science). Confocal images were acquired on an Olympus FluoView 1000  inverted 
microscope equipped with a PlanApo 60/1.10 oil objective (Olympus, Center Valley, PA). 
Images were analysed with ImageJ 1.46i (National Institutes of Health, Bethesda, MD)  
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 Figure legends 
Figure 1 Validation of selected genes upregulated in microarray analysis by RT-qPCR. (a) 
Expression of CCL5, TLR3, CXCL10 and OAS2 was determined in untransfected cells (untr) 
and after liposome transfection of mock and different smiRs and anti-miRs in hBM-MSCs as 
indicated in the figure. CCL5 and CXCL10 were also determined following transfection by 
electroporation. Circle, triangle and rhombus symbols represent mean values of technical 
triplicates from three different donors. The mean ± SEM of the biological triplicates are 
shown by vertical lines. (b) Expression of CCL5, TLR3, CXCL10 and OAS2 in untransfected 
hAC and after liposome transfection of mock and indicated smiRs. CCL5 and CXCL10 were 
also determined following transfection by electroporation. Circle and rhombus symbols 
represent mean values of technical triplicates from two different donors. The mean ± SEM of 
the biological duplicates are shown by vertical lines. ND = not detected. 
 
Figure 2 Cytokine secretion. (a) Concentration of CCL5 and CXCL10 proteins secreted into 
the culture medium by hBM-MSCs. Technical duplicates were used for each donor. Data are 
shown as mean ± SEM of the biological triplicates. (b) Concentration of CCL5 and CXCL10 
proteins secreted by hACs. Technical duplicates were used for each donor. Data are shown 
as mean ± SEM of biological duplicates. ND = not detected. 
 
Figure 3 Knockdown of TLR signaling and inhibition of endosomal acidification. Cells 
were treated with scrambled siRNA, TLR3 siRNA and MYD88 siRNA by electroporation 
(a) two days before liposomal transfection of smiR-145. Before the smiR-145 transfection 
the TLR3 and MYD88 knockdown were measured using RT-qPCR (white bars) using cells 
from one hBM-MSC donor and shown as mean ± SD of technical triplicates. CCL5 and 
CXCL10 mRNA levels were measured one day after smiR-145 transfection (grey bars). (b) 
shows knockdown of TLR3 and MYD88 at the protein level. The effect of different doses of 
chloroquine on the expression of CCL5 (c) and CXCL10, (d) following smiR-145 liposomal 
transfection. Circle and rhombus symbols represent mean values of technical triplicates from 
two donors. Also 100 μM and 500 μM chloroquine was used, but all cells died at these 
concentrations and the results are therefore not included. CQ = chloroquine. ND = not 
detected. 
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Figure 4 Confocal microscopy of smiR delivery. Cells (hBM-MSCs from one donor) were 
transfected using a FAM-labeled smiR. At indicated time points cells were stained with 
antibodies against EEA1, CD63 and LAMP1. Green = FAM-labeled smiR, red = EEA1, 
CD63 or LAMP1, blue = DAPI. Scalebar = 10 μm 
 
Figure 5 Validation and knockdown of PKR and RIG-I expression. Expression of PKR (a) 
and RIG-I (b) after transfection of mock and indicated smiRs. hBM-MSCs were treated with 
scrambled, PKR (c) and RIG-I (d) siRNA by electroporation two days before liposomal 
transfection of smiR-145. Before the smiR-145 transfection the PKR and RIG-I knockdown 
was measured using RT-qPCR. CCL5 and CXCL10 mRNA levels were measured one day 
after smiR-145 transfection. In (c) the results from one donor are shown as mean ± SD using 
technical triplicates. In (d) the circle, triangle and rhombus symbols represent mean values of 
technical triplicates from three different donors. The mean ± SEM of the biological 
triplicates are shown by vertical lines. In (e) the concentration of CCL5 and CXCL10 
proteins secreted into the culture medium is shown as the mean ± SEM of the results from 
two of the donors, showing that protein levels were also efficiently reduced after smiR.145 
transfection when the cells had been pre-treated with RIG-I siRNA.. Technical duplicates 
were used for each donor. In (f) cells were treated with scrambled and RIG-I siRNA by 
electroporation two days before smiR-145 liposomal transfection. Western blotting using 
antibodies against RIG-I were performed 6 and 24 hours after transfection (one hBM-MSC 
donor). Predicted molecular weight of RIG-I is 101 kDa. * = non specific bands. 
 
Figure 6 Overexpression and knockdown of RIG-I in 293TN cells. (a) RIG-I mRNA levels 
were determined after liposomal transfection of mock, smiR-145, control construct (EGFP) 
and different RIG-I constructs as indicated in the figure. (b) A representative Western 
blotting image using antibodies against RIG-I in untransfected (right lane) and RIG-I 
transfected 293 TN cells (full length RIG-I + GFP, predicted molecular weight 
approximately 130 kDa). (c) CCL5 and (d) CXCL10 mRNA were measured after liposome 
transfection of indicated smiRs and plasmids. Protein levels of CCL5 (e) and CXCL10 (f) 
were measured after liposome transfection of indicated smiRs and plasmids. (g) mRNA and 
(h) protein levels after liposome co-transfection of RIG-I siRNA and full-length RIG-I 
plasmids relative to co-transfection of scrambled control siRNA and full-length RIG-I 
plasmid. mRNA levels (in a, c, d and g) are shown as mean ± SD from technical triplicates. 
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Protein levels (in e, f and h) are shown as mean ± SD from technical duplicates. ND = not 
detected. 
 
Figure 7 Induction of miRINIR using smiR-145 and smiR-145 mutants from Qiagen. CCL5 
and CXCL10 were measured after transfection of smiR molecules from Ambion (A) and 
Qiagen (Q) (a). smiR-642a and smiR-331 from did not lead to immune response (smiRs 
from Ambion) (b). Mutating the poly (UUUU) of smiR-145 reduced the immune response 
(c).  Results in (a) and (b) are from two different donors and shown as mean ± SD from 
technical triplicates. In (c) circle, triangle and rhombus symbols represent mean values of 
technical triplicates from three donors. The mean ± SEM of the biological triplicates are 
shown by vertical lines. Numbers in parentheses indicate % expression relative to smiR-145-
Q. ND = not detected.  
 
Figure 8 Immune response to liposomes following mock transfection and transfection of 
smiR-neg and smiR-145 in hBM-MSCs. Quantification of interleukin gene expression of 
IL6, IL8 and IL1B using RT-qPCR (a) and IL8 protein synthesis using the Luminex system 
(b). In (a) circle, triangle and rhombus symbols represent mean values of technical triplicates 
from three different donors. The mean ± SEM of the biological triplicates are shown by 
vertical lines. In (b) technical duplicates were used for each donor. Data are shown as mean 
± SEM of the biological triplicates. In (c) cells were treated with scrambled and RIG-I 
siRNA by electroporation two days before liposomal mock transfection. Before the mock 
transfection RIG-I knockdown was measured using RT-qPCR. CCL5, CXCL10, IL6, IL8 
and, IL1B mRNA levels were measured one day after mock transfection. Circle, triangle and 
rhombus symbols represent mean values of technical triplicates from three different donors. 
The mean ± SEM of the biological triplicates are shown by vertical lines. 
 








Supplementary material 
 
Supplementary Figure S1. Effective delivery and activity of smiR control. smiR-1 was used 
as a positive control as recommended by the manufacturer. smiR-1 should lead to degradation 
of PTK9 mRNA. PTK9 levels were measured by RT-qPCR after transfection of smiR-neg 
control and smiR-1 using liposomes or electroporation.  Black, blue and red symbols 
represent mean values from technical triplicates from three different donors. The mean ± 
SEM of the biological triplicates are shown by vertical lines. 
 
 
 Supplementary Figure S2. Expression of (A) IRF3 and (B) IRF7 mRNA was determined in 
untransfected (untr) cells and after transfection of mock, smiR-neg and smiR-145 (hBM-MSC 
donor 1). Results are shown as mean ± SD from technical triplicates. 
 
 
 
 
Supplementary Figure S3. Endogenous expression of miR-145 relative to U6 in 
untransfected cells determined using RT-qPCR. Black, blue and red symbols represent mean 
values of technical triplicates from three different donors (hBM-MSC donor 1, 2 and 3). The 
mean ± SEM of the biological triplicates are shown by vertical lines. 
 
 
 
Supplementary Figure S4 Liposomal transfection of smiRs, dose-response and time kinetics. 
Expression of CCL5 (a), (c), (e), and (g) and CXCL10 (b), (d), (f), and (h) after liposomal 
transfection of different smiRs (a, b, hBM-MSC donor 4), in response to different doses of 
lipofectamine (mock) (c, d, hBM-MSC donor 5, passage 3), in response to different 
concentrations of smiR-145 (e, f, hBM-MSC donor 5, passage 4) and in the course of a time 
kinetics of gene expression experiment (g, h, hBM-MSC donor 6). All results are shown as 
mean ± SD from technical triplicates using cells from one donor. ND = not detected. 
 
 
 
 
Supplementary Figure S5. Transfection of smiR-1 using liposomes (Lipofectamine) at 25 
nM results in the same knockdown of PTK9 mRNA as electroporation of smiR-145 (3 μM). 
Results are shown as mean ± SD from technical triplicates of one donor (hBM-MSC donor 5). 
 
 
 
 
Supplementary Figure S6. Transfection using siPORT liposome transfection reagent. (a) 
Knockdown of PTK9 after transfection of smiR-1. Expression of CCL5 (b) and CXCL10 (c) 
mRNA in untransfected cells and after transfection of mock (8 and 16 μl siPORT) and smiR-
145 as indicated in the figure. Results are shown as mean ± SD from technical triplicates of 
one donor (hBM-MSC donor 5). N.D = not detected. 
 
 
 
Supplementary Figure S7. RIG-I knockdown using siRNAs from Qiagen. Cells were treated 
with scrambled and RIG-I siRNA by electroporation two days before liposomal transfection 
of smiR-145. Before the smiR-145 transfection RIG-I knockdown was measured using RT-
qPCR. CCL5 and CXCL10 mRNA levels were measured one day after smiR-145 transfection. 
Black and blue symbols represent mean values of technical triplicates from two different 
donors (hBM-MSC donor 9 and 10). The mean ± SEM of the biological duplicates are shown 
by vertical lines. 
 
 
Supplementary Figure S8 Transfection of RIG-I constructs in 293TN cells. (a) shows 
mRNA expression of RIG-I, CCL5 and CXCL10 after transfection of the different construct as 
indicated on the X-axis.  Results are shown as mean ± SD from technical triplicates. All 
constructs resulted in GFP expression (b) and all the expressed proteins had the expected size 
as checked by western blotting using anti-RIG-I and anti-GFP antibodies (c). 
 
Supplementary Figure S9 Comparison of smiR-145 sequences from Ambion and Qiagen 
and PTK9 knockdown using smiR-1 from Qiagen. The 2 nucleotide 3’-overhang of the 
mature strand of Ambions smiR molecules always consist of the 2 last nucleotides from the 
mature endogenous miRNA sequence, while the overhang at the complementary strand is 
always a TT (a). Knockdown of PTK9 after smiR-1-Q transfection was used as a positive 
control (b). Results are shown as mean ± SD from technical triplicates of one donor (hBM-
MSC donor 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S1. Summary of some of the reagents used  
Taqman Assays 
Gene symbol Gene name Company Cat no. 
CXCL10 Chemokine (C-X-C motif) ligand 10 Applied 
Biosystems 
Hs00171042_m1 
CCL5 Chemokine (C-C motif) ligand 5 Applied 
Biosystems 
Hs00174575_m1 
TLR3 Toll-like receptor 3 Applied 
Biosystems 
Hs01551078_m1 
MYD88 Myeloid differentiation primary 
response gene 88 
Applied 
Biosystems 
Hs00182082_m1 
OAS2 2’-5’-oligoadenylate synthetase 2, 
69/71kDa 
Applied 
Biosystems 
Hs00213443_m1 
DDX58 (RIG-I) DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 
Applied 
Biosystems 
Hs00204833_m1 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
Applied 
Biosystems 
Hs99999905_m1 
TWF1 (PTK9) Actin-binding protein, homolog 1 Applied 
Biosystems 
Hs00702289_s1 
EIF2AK2 (PKR) Eukaryotic translation initiation factor 
2-alpha kinase 2 
Applied 
Biosystems 
Hs00169345_m1 
 
MicroRNA/small RNA assays 
Interim/gene symbol RNA name Company Cat no. 
Mir145 miR-145 Applied 
Biosystems 
001141 
RNU6-1 (U6) RNA, U6 small nuclear 1 Applied 
Biosystems 
001973 
 
smiR and anti-miR molecules 
Name Sequence 5’-3’ Company Cat no. 
Pre-negative control no 1 N/A Ambion AM17110 
FAM-labeled Pre-negative 
control no 1 
N/A Ambion AM17121 
Pre-miR-145 guccaguuuucccaggaaucccu Ambion PM11480 
Pre-miR-140-5p cagugguuuuacccuaugguag Ambion PM10205 
Pre-miR-30d uguaaacauccccgacuggaag Ambion PM10756 
Pre-miR-143 ggugcagugcugcaucucuggu Ambion PM10883 
Pre-miR-451 aaaccguuaccauuacugaguu Ambion PM10286 
Pre-miR-563 agguugacauacguuuccc Ambion PM11418 
Pre.miR-642a gucccucuccaaaugugucuug Ambion PM11477 
Pre-miR-331 cuagguauggucccagggaucc Ambion PM11179 
Pre-miR-1 (positive control) uggaauguaaagaaguauguau Ambion AM17150 
Anti-negative control no 1 N/A Ambion AM17010 
Anti-miR-145 N/A Ambion AM11480 
Anti-miR-140-5p N/A Ambion AM10205 
miScript-145  guccaguuuucccaggaaucccu Qiagen MSY0000437 
miScript-1 uggaauguaaagaaguauguau Qiagen MSY0000416 
 
Silencer select Pre-design and validated siRNA 
Name  Company Cat no. 
Silencer negative control no 2  Ambion AM4637 
TLR3  Ambion s235 
MYD88  Ambion s9138 
PKR  Ambion s11185 
RIG-I  Ambion s24143 
Allstars negative control  Qiagen 1027280 
RIG-I  Qiagen SI03019646 
 
Antibodies 
Primary antibodies Protein name Company Cat.no 
Mouse anti-EEA1 Early endosome antigen 1   
Mouse anti-CD63 CD63 molecule Developmental 
Studies 
H5C6 
Hybridoma Bank 
Mouse anti-LAMP1 Lysosomal-associated membrane 
protein 1 
Developmental 
Studies 
Hybridoma Bank 
H4A3 
Mouse anti-GFP Green fluorescent protein Clontech 632381 
Goat anti-RIG-I (C-15) DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 
Santa Cruz sc-48929 
Mouse anti-TLR3 Toll-like receptor 3 Abcam Ab13915 
Rabbit anti-MYD88 Myeloid differentiation primary 
response gene 88 
Abcam Ab1333739 
Mouse anti-ACTB Actin, beta Abcam Ab8226 
 
Secondary antibodies  Company Cat no. 
Donkey anti-goat (HRP)  Jackson 
ImmunoResearch 
705-035-147 
Goat anti-Rabbit (HRP)  Vector labs PI-1000 
Horse anti-Mouse (HRP)  Vector labs PI-2000 
Donkey anti-mouse (Cy3)  Jackson 
ImmunoResearch 
715-165-151 
    
Singleplex assays  Company Cat no. 
Rantes (CCL5)  Biorad 171B5025M 
IP-10 (CXCL10)  Biorad 171B5020M 
IL-8  Biorad 171B5008M 
N/A – not available 
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Supplementary Table S3 
 
Gene Ontology analysis of genes differently expressed after Lipofectamine transfection of 
smiR-145 
 
  Upregulated             Downregulated 
 
GO term  GO term 
Regulation of viral protein levels in host 
cell  Translational elongation 
Intracellular transport of viral proteins in 
host cell  Viral genome expression 
Antigen processing and presentation of 
peptide antigen via MHC class I  Viral transcription 
Antigen processing and presentation of 
endogenous peptide antigen  Translational termination 
Lymphocyte chemotaxis  Viral infectious cycle 
Base conversion or substitution editing  Endocrine pancreas development 
Antigen processing and presentation of 
endogenous peptide antigen via MHC class 
I  Viral reproductive process 
Negative regulation of viral reproduction  Structural constituent of ribosome 
Antigen processing and presentation of 
peptide antigen  Ribosome 
Regulation of defense response to virus by 
host  Endocrine system development 
MHC class I receptor activity  Taxis 
MHC class I protein complex  Chemotaxis 
MHC protein complex  Translation 
Antigen processing and presentation  Actin binding 
Positive regulation of adaptive immune 
response based on somatic recombination 
of immune receptors built from 
immunoglobulin superfamily domains  Viral reproduction 
Regulation of adaptive immune response 
based on somatic recombination of 
immune receptors built from 
immunoglobulin superfamily domains  Cell proliferation 
MHC protein binding  Structural molecule activity 
Negative regulation of interferon type I 
production  Oxidoreductase activity 
Cytokine and chemokine mediated 
signaling pathway  Cytosol 
Regulation of interferon type I production  System development 
Interferon type I production  Protein binding 
Defense response to virus  Multicellular organismal development 
Response to virus  Cellular metabolic process 
Response to cytokine stimulus  Cellular protein metabolic process 
Positive regulation of inflammatory 
response  Cellular macromolecule metabolic process 
Chemokine activity  Cytoplasmic part 
Regulation of defense response to virus  Cellular process 
Chemokine receptor binding  Cytoplasm 
Regulation of smooth muscle cell 
proliferation  Developmental process 
JAK-STAT cascade  Catalytic activity 
 
 
 
Supplementary Table S4a 
 
Genes differently expressed after electroporation of smiR-145 
 
Upregulated     Downregulated 
 
Gene symbol Fold Change q-value  Gene symbol Fold change q-value 
ACTG2 2,24 0,003  TMEM9B -3,13 0 
    FSCN1 -3,11 0 
    GMFB -2,42 0 
    FAM3C -2,31 0 
    C6orf115 -2,09 0 
    CBFB -2,08 0 
    SWAP70 -2,00 0 
    C5orf15 -2,03 0 
    PSAT1 -2,00 0,001 
 
A threshold of 2-fold and q-value <0.05 (adjusted p-value) was used to generate lists of differently 
expressed genes. 
 
 
 
Supplementary Table S4b 
 
Downregulated genes common for electroporation and lipofectamine 
 
Electroporation     Liposomal transfection 
 
Gene symbol Fold change q-value  Gene symbol Fold change q-value 
TMEM9B -3,13 0  TMEM9B -2,07 0,012 
FSCN1 -3,11 0  FSCN1 -4,44 0 
GMFB -2,42 0  GMFB -2,35 0,003 
FAM3C -2,31 0  FAM3C -2,25 0,006 
CBFB -2,08 0  CBFB -2,11 0,010 
SWAP70 -2,00 0  SWAP70 -2,29 0,005 
PSAT1 -2,00 0,001  PSAT1 -2,73 0,001 
 
A threshold of 2-fold and q-value <0.05 (adjusted p-value) was used to generate lists of differently 
expressed genes. 
Supplementary Table S5  
Sequence alignment of miR-145 with miR-642a, miR-331 and miR-140 (5’Æ3’) 
 
    GUCCAGUUUUCCCAGGAAUCCCU (miR-145) 
    GUCCCUCUCCAAAUGUGUCUUG (miR-642a) 
  
 
    GUCCAGUUUUCCCAGGAAUCCCU (miR-145) 
    CUAGGUAUGGUCCCAGGGAUCC  (miR-331)  
 
    GUCCAGUUUUCCCAGGAAUCCCU (mir-145) 
    CAGUGGUUUUACCCUAUGGUAG   (mir-140) 
 
 
 
 
 
 
Supplementary Table S2
Upregulated and downregulated genes in MSCs transfected with smiR-145 using
 lipofectamine (compared to smiR-neg control)
A threshold of 2-fold and q-value <0.05 (adjusted p-value) was used to 
generate lists with differently expressed genes
Gene Fold Change q-value Gene Fold Change q-value
CXCL10 166.5 0 ACO1 -11.6 0
TNFSF10 98.2 0 AKR1B10 -8.6 0
IFIT2 73.1 0 IFI6 -7.8 0
OASL 68.3 0 NT5DC2 -5.5 0
CCL5 58.2 0 PLAU -5.2 0
HERC5 56.3 0 GLS -4.5 1.79E-04
RSAD2 51.2 0 GDF15 -4.5 1.79E-04
CCL5 49.7 0 FSCN1 -4.4 1.79E-04
ISG20 43.2 0 ARHGDIB -4.3 1.79E-04
IFNB1 35.1 0 TXNDC12 -3.9 1.79E-04
CXCL11 34.2 0 KIAA0114 -3.7 1.79E-04
IFIT3 34.1 0 GPR68 -3.7 1.79E-04
GBP4 31.8 0 TMEM119 -3.7 1.79E-04
IFIT3 31.2 0 PAMR1 -3.5 2.50E-04
IL18BP 30.2 0 CDKN2B -3.5 2.50E-04
IFIH1 29.4 0 RAB3IL1 -3.2 2.50E-04
IFI27 28.9 0 WRB -3.2 2.50E-04
TNFSF13B 28.6 0 PRKCA -3.1 2.50E-04
MX2 24.9 4.31E-05 CERK -3.1 2.50E-04
TNFSF13B 24.0 4.31E-05 LRRC17 -3.1 4.00E-04
OAS3 20.5 4.31E-05 CMBL -3.1 4.00E-04
CCL8 19.9 4.31E-05 RPS23 -3.1 4.00E-04
BST2 19.5 4.31E-05 CDKN2B -3.1 6.25E-04
OAS1 18.3 4.31E-05 KRT10 -3.0 4.00E-04
DDX58 18.1 4.31E-05 CXCL6 -3.0 0.001410256
OASL 17.9 4.31E-05 FAP -3.0 9.09E-04
OAS2 17.6 4.31E-05 HNRPA1P4 -2.9 5.56E-04
MX1 17.5 4.31E-05 DLEU1 -2.9 5.56E-04
IFIT1 17.0 4.31E-05 MTSS1 -2.9 0.001861702
IDO1 16.7 4.31E-05 MAP4K4 -2.9 6.67E-04
GBP1 16.6 4.31E-05 CERK -2.8 6.67E-04
INDO 16.1 4.31E-05 AKR1C2 -2.8 0.002541667
GBP1 15.9 4.31E-05 ODC1 -2.8 8.87E-04
CFB 15.9 4.31E-05 MAP4K4 -2.8 9.09E-04
OAS1 15.9 4.31E-05 C5orf21 -2.7 9.56E-04
OAS2 15.5 4.31E-05 PSAT1 -2.7 0.001351351
ISG15 15.0 4.31E-05 UBE2C -2.7 0.00297619
IFIT1 14.9 4.31E-05 CLDN11 -2.7 0.002366071
IFI44L 14.6 4.31E-05 LOC643873 -2.7 0.001214286
HES4 14.4 4.31E-05 EIF4B -2.7 0.00125
KIF5C 13.5 4.31E-05 HNRPA1L-2 -2.7 0.001428571
LGALS9 13.0 4.31E-05 C20orf100 -2.7 0.002107843
OAS1 13.0 4.31E-05 GEM -2.7 0.001666667
GBP5 12.7 4.31E-05 LOC729779 -2.7 0.001381579
IFITM1 12.5 4.31E-05 PBK -2.7 0.00297619
HERC6 12.5 4.31E-05 ZMAT3 -2.6 0.002107843
CMPK2 12.3 4.31E-05 WNT5A -2.6 0.002366071
IRF7 12.2 4.31E-05 BEND6 -2.6 0.001428571
SLC15A3 12.2 4.31E-05 LOC400455 -2.6 0.001647727
EPSTI1 12.1 4.31E-05 NAP1L1 -2.6 0.001569767
LOC100129681 12.1 4.31E-05 TSPAN6 -2.6 0.001847826
USP18 11.8 4.31E-05 ALDH1A3 -2.6 0.001428571
RTP4 11.8 4.31E-05 FAM172A -2.6 0.001875
IFI6 11.5 4.31E-05 FAM173B -2.6 0.002163462
IRF7 11.0 4.31E-05 HMOX1 -2.6 0.002366071
PRIC285 10.8 4.31E-05 PCYOX1 -2.6 0.002541667
RARRES3 10.8 4.31E-05 IARS -2.6 0.002366071
CKB 10.5 4.31E-05 C18orf55 -2.6 0.002040816
AIM2 10.0 7.25E-05 MLPH -2.5 0.004077381
SAMD9 9.7 7.25E-05 GLT8D2 -2.5 0.00359589
SAMD9L 9.7 7.25E-05 FAM171A1 -2.5 0.002541667
PARP14 9.6 7.25E-05 LOC646688 -2.5 0.003115385
LOC100128274 9.5 7.25E-05 LOC388275 -2.5 0.0037
ZC3HAV1 9.4 7.25E-05 HNRNPA0 -2.5 0.002745902
CASP1 9.4 7.25E-05 - OLFML2A -2.5 0.006651376
CASP1 9.4 7.25E-05 LXN -2.5 0.00494382
HLA-F 9.3 7.25E-05 LPXN -2.5 0.003506944
LAP3 9.2 7.25E-05 PYCR1 -2.5 0.003085938
IFI35 8.8 1.28E-04 VAT1 -2.5 0.003963415
KIAA1618 8.7 7.25E-05 C7orf41 -2.5 0.003506944
HIST2H2AA4 8.3 1.28E-04 MYH10 -2.5 0.004066265
HIST2H2AA3 8.3 1.28E-04 LOC100129673 -2.4 0.00375
XAF1 8.3 1.56E-04 TGFBR2 -2.4 0.003432836
GCH1 8.2 1.28E-04 FAM43A -2.4 0.003219697
TYMP 8.2 1.28E-04 DTD1 -2.4 0.003506944
TYMP 8.2 1.28E-04 PCYOX1 -2.4 0.003963415
GJD3 8.1 1.28E-04 ALDH1A3 -2.4 0.003455882
PARP12 8.0 1.28E-04 KCNMA1 -2.4 0.004738372
BATF2 7.9 1.28E-04 CCDC34 -2.4 0.003506944
PARP9 7.8 1.56E-04 PGD -2.4 0.004744318
PSMB9 7.7 2.08E-04 TACC2 -2.4 0.003682432
ECGF1 7.5 2.15E-04 LOC649049 -2.4 0.003963415
WARS 7.5 2.08E-04 APPL2 -2.4 0.003963415
CLDN23 7.4 2.15E-04 LOC730107 -2.4 0.003963415
LOC389386 7.3 1.83E-04 TOP2A -2.4 0.0081875
APOBEC3G 7.3 1.83E-04 IMPDH2 -2.4 0.006651376
PLEKHA4 7.2 2.15E-04 CMTM8 -2.4 0.004741379
TAP1 7.2 2.15E-04 TOX2 -2.4 0.005241935
IFI44 7.2 2.15E-04 LOC392437 2.4 0.005833333
HIST2H2AC 7.0 2.15E-04 GMFB -2.4 0.003963415
APOBEC3G 7.0 2.15E-04 RPLP0 -2.3 0.005083333
DDX60L 7.0 2.15E-04 LOC729423 -2.3 0.005241935
IFIT3 6.9 2.81E-04 LOC642741 -2.3 0.006504854
TAP2 6.9 2.15E-04 SLC14A1 -2.3 0.005850515
CXCL16 6.9 4.01E-04 CD59 -2.3 0.006651376
WARS 6.6 2.60E-04 CXCL6 -2.3 0.009392857
XAF1 6.6 4.42E-04 CXCL1 -2.3 0.008955224
DHX58 6.5 3.03E-04 TTC3 -2.3 0.005526316
MYD88 6.5 2.37E-04 PIR -2.3 0.006504854
CCL2 6.5 2.37E-04 POPDC3 -2.3 0.00510989
LOC400759 6.3 2.81E-04 SWAP70 -2.3 0.005319149
NCOA7 6.3 3.19E-04 ODZ4 -2.3 0.010098684
SP110 6.2 3.19E-04 EIF3L -2.3 0.006464646
STX11 6.1 3.19E-04 MGP -2.3 0.008778195
PARP9 6.1 4.09E-04 BAX -2.3 0.006651376
TLR3 6.1 3.33E-04 UBE2C -2.3 0.009827586
TRIM21 6.1 3.33E-04 TRIB3 -2.3 0.006464646
PLSCR1 6.0 3.33E-04 C17orf45 -2.3 0.007146018
TMEM140 5.9 4.57E-04 E2F7 -2.3 0.006651376
ZMYND15 5.8 4.62E-04 FTH1 -2.3 0.006651376
APOL3 5.8 4.62E-04 DLGAP5 -2.3 0.010400641
HIST2H2AA3 5.8 4.84E-04 FAM3C -2.3 0.006504854
LOC643384 5.8 4.09E-04 MGAT4B -2.3 0.006909091
HLA-B 5.8 4.42E-04 SH3PXD2A -2.2 0.00822314
GMPR 5.7 4.09E-04 WRB -2.2 0.006504854
SP110 5.7 4.42E-04 KCTD12 -2.2 0.010098684
IL29 5.7 4.09E-04 F2R -2.2 0.00726087
ECGF1 5.7 4.62E-04 C7orf10 -2.2 0.011691617
FBXO6 5.6 4.62E-04 LOC100129550 -2.2 0.007117117
ZNFX1 5.5 4.67E-04 CDCA3 -2.2 0.010211039
GBP2 5.5 4.67E-04 NMB -2.2 0.014243902
C19orf66 5.4 4.67E-04 TCTEX1D2 -2.2 0.007456897
TDRD7 5.4 4.57E-04 KLHL5 -2.2 0.008067227
PARP10 5.3 5.20E-04 SNHG9 -2.2 0.007146018
TRIM22 5.3 6.69E-04 LOC642357 -2.2 0.008962963
PPM1K 5.3 4.67E-04 LOC100133328 -2.2 0.009251825
ASPHD2 5.1 6.73E-04 RPL15 -2.2 0.007987288
MLKL 5.1 5.75E-04 EIF3L -2.2 0.008352713
ZC3HAV1 5.1 6.73E-04 RPL10A -2.2 0.008352713
NT5C3 5.1 6.73E-04 UBE4B -2.2 0.00758547
HRASLS2 5.1 9.93E-04 RPS6P1 -2.2 0.008352713
CD74 5.1 9.93E-04 GSTA4 -2.2 0.00726087
TAP2 5.0 8.58E-04 LOC392437 -2.2 0.008560606
UBA7 5.0 8.02E-04 GREM2 -2.2 0.009827586
HLA-E 5.0 7.33E-04 MFAP5 -2.2 0.01492823
TAC3 5.0 0.001192053 DLGAP5 -2.2 0.012472527
NT5C3 5.0 7.25E-04 ARL6IP5 -2.2 0.008352713
PNPT1 4.9 7.33E-04 SVIL -2.2 0.008352713
RNF213 4.9 8.58E-04 PMEPA1 -2.2 0.008352713
TRIM5 4.8 8.52E-04 GPSM2 -2.2 0.013389175
UBE2L6 4.8 9.89E-04 C9orf119 -2.2 0.008560606
TMEM62 4.7 9.24E-04 LRRC17 -2.2 0.010370968
PARP10 4.7 0.001034483 ICAM3 -2.2 0.008560606
C15orf48 4.7 0.001403226 CDKN3 -2.2 0.014855769
STAT1 4.7 0.001073826 TMEM204 -2.2 0.009392857
UNC93B1 4.6 0.001031469 LOC647276 -2.2 0.013346354
PARP10 4.6 0.001054422 PSPH -2.2 0.009347826
HCP5 4.6 0.001820809 RPL23 -2.2 0.009827586
GCH1 4.6 0.001003521 C6orf85 -2.2 0.012472527
CD38 4.6 0.00183908 RPL4 -2.2 0.010211039
RASGRP3 4.5 0.001034483 GNPDA1 -2.2 0.008352713
SEPT4 4.5 0.001054422 SHISA2 -2.2 0.011763006
PMAIP1 4.4 0.001073826 SH3D19 -2.2 0.008352713
HLA-F 4.4 0.004090909 FAM129A -2.2 0.009751773
SP110 4.4 0.001133333 NTN4 -2.1 0.010461783
CD74 4.4 0.001575758 EEF1A1 -2.1 0.009914966
HLA-H 4.3 0.002261905 RPL37A -2.1 0.010660377
KCTD14 4.3 0.001200658 RPL17 -2.1 0.00989726
APOBEC3F 4.2 0.001233766 CDC20 -2.1 0.016860987
SERPING1 4.2 0.002769608 CCNB2 -2.1 0.018877119
HLA-C 4.2 0.001433121 FHOD1 -2.1 0.009080882
OAS2 4.2 0.001575758 LOC642934 -2.1 0.011370482
HIST2H2BE 4.2 0.002346154 PTPN11 -2.1 0.011729651
APOL1 4.2 0.001455696 SIRPA -2.1 0.009827586
LYSMD2 4.1 0.001426282 CMTM4 -2.1 0.010016667
NFE2L3 4.1 0.001493711 SLC16A6 -2.1 0.012472527
SLC25A28 4.1 0.0015 CBFB -2.1 0.010016667
STAT1 4.1 0.001864407 MRPL51 -2.1 0.010016667
APOL2 4.1 0.001575758 LOC728492 -2.1 0.011729651
USP41 4.0 0.001568323 RBPMS2 -2.1 0.016440092
RSPO3 4.0 0.00206044 RPL3 -2.1 0.013115183
IRF1 4.0 0.001686391 EVI2A -2.1 0.010632911
MSX1 4.0 0.001616766 FNBP1 -2.1 0.010740741
ARL9 3.9 0.001616766 IL8 -2.1 0.011729651
EIF2AK2 3.9 0.001787791 NDP -2.1 0.017059471
CD68 3.9 0.002865854 LOC645387 -2.1 0.011960227
TRIM38 3.9 0.001864407 UHRF1 -2.1 0.018474026
PHF15 3.9 0.001783626 BZW2 -2.1 0.013085106
CTNNBL1 3.9 0.001622024 TGFBR2 -2.1 0.010945122
MDK 3.9 0.002053073 ITGAE -2.1 0.011318182
TRIM5 3.9 0.001783626 C18orf55 -2.1 0.010751534
CCL7 3.8 0.003220721 TMEM5 -2.1 0.010740741
LGALS9 3.8 0.00206044 FAM89B -2.1 0.010740741
DDX60 3.8 0.002261905 NPM3 -2.1 0.012472527
PSMB8 3.8 0.001924157 SUMF1 -2.1 0.012513587
KRTAP1-5 3.8 0.001864407 LOC647030 -2.1 0.011867816
HCG4 3.8 0.007716049 HJURP -2.1 0.01745614
MDK 3.8 0.002346154 TMEM9B -2.1 0.012161017
BDKRB1 3.8 0.003650628 C18orf56 -2.1 0.013085106
LOC728946 3.7 0.002261905 LOC158345 -2.1 0.015981308
GCA 3.7 0.002131148 NDFIP2 -2.1 0.011729651
PSMB8 3.7 0.002055556 C16orf53 -2.1 0.014002525
STAT2 3.7 0.002261905 CMTM4 -2.1 0.011960227
EHD4 3.6 0.002261905 AGBL5 -2.1 0.014243902
CFLAR 3.6 0.002939815 ARPC1A -2.1 0.013085106
LOC389386 3.6 0.002261905 GCLM -2.1 0.012513587
PSMB8 3.6 0.002342932 PTPN13 -2.1 0.013085106
MLKL 3.6 0.002302632 GALNT11 -2.1 0.011729651
PSME2 3.5 0.002346154 LOC100131940 -2.1 0.013115183
IL4I1 3.5 0.002461735 RPL13A -2.1 0.013115183
PANX1 3.5 0.00234375 FOXRED2 -2.0 0.014243902
MICB 3.5 0.002512563 LOC729926 -2.0 0.016869469
IFI16 3.5 0.002474619 CC2D2A -2.0 0.014243902
UBE2L6 3.5 0.002939815 LAGE3 -2.0 0.013718274
C1R 3.5 0.003373894 KDELR3 -2.0 0.015797619
TLR3 3.5 0.0025375 HSBP1 -2.0 0.013389175
LGMN 3.5 0.003650628 EPHX1 -2.0 0.015868545
RHBDF2 3.5 0.002512563 MOCS2 -2.0 0.013718274
LGALS3BP 3.5 0.002939815 FAM45A -2.0 0.015849057
C1R 3.5 0.003506494 LOC645638 -2.0 0.02219697
KRT34 3.5 0.002769608 NIPSNAP1 -2.0 0.014243902
LOC100133019 3.4 0.00288835 CTHRC1 -2.0 0.019989583
APOL2 3.4 0.002636816 FMNL2 -2.0 0.022817164
PHACTR4 3.4 0.002660891 CORO2B -2.0 0.016337209
ADAR 3.4 0.002939815 MGP -2.0 0.02728013
NEFM 3.4 0.004137597 NBL1 -2.0 0.018766094
BTN3A3 3.4 0.003038991 TXNRD1 -2.0 0.016869469
C4orf33 3.4 0.002939815 ABCE1 -2.0 0.014243902
PSMB10 3.4 0.002939815 BRI3BP -2.0 0.013718274
C6orf192 3.4 0.002939815 EIF3F -2.0 0.016440092
NUB1 3.4 0.002939815 FAM3C -2.0 0.014243902
XRN1 3.4 0.002939815 FAM64A -2.0 0.032875354
TRAFD1 3.3 0.002939815 MLLT11 -2.0 0.014660194
CH25H 3.3 0.003482533 CCNG1 -2.0 0.015849057
UNC93B1 3.3 0.003045455 AGPAT9 -2.0 0.016869469
GSDMD 3.3 0.003045455 LOC641814 -2.0 0.02219697
GAL3ST4 3.3 0.002995392 LOC641814 -2.0 0.02219697
OPTN 3.3 0.003373894
PML 3.3 0.00321267
C10orf10 3.3 0.003816872
CD68 3.3 0.003791322
ACSL5 3.2 0.003650628
LOC654346 3.2 0.003551502
SP100 3.2 0.003340807
APOBEC3F 3.2 0.003551502
SP110 3.2 0.003480176
LGMN 3.2 0.005008993
LRRN3 3.2 0.004023904
LOC285296 3.2 0.003359375
HLA-DRA 3.2 0.006064189
SLC16A4 3.2 0.00565331
TRIM25 3.2 0.003650628
HLA-A29.1 3.2 0.01723382
MOV10 3.2 0.00348913
IL7R 3.2 0.006059322
ADAR 3.2 0.003650628
OGFR 3.2 0.003482533
FLJ21986 3.1 0.005
LBA1 3.1 0.003941532
MIR155HG 3.1 0.003682573
LOC730743 3.1 0.004581784
LRRN3 3.1 0.003941532
RAB8B 3.1 0.003677083
BIRC3 3.1 0.004189189
STAT1 3.1 0.004224138
SLC2A12 3.1 0.003650628
LOC728255 3.1 0.004530075
HK2 3.1 0.004127451
MLKL 3.0 0.003903689
RNF114 3.0 0.003941532
MASTL 3.0 0.003945783
JAK2 3.0 0.004137597
LGALS9B 3.0 0.004601852
MASTL 3.0 0.003941532
BAMBI 3.0 0.004023904
CARD16 3.0 0.004221154
GNB4 3.0 0.004137597
MT1M 3.0 0.005292553
MMP13 3.0 0.004640221
IL33 3.0 0.028560359
DUSP19 3.0 0.004581784
PFKFB4 3.0 0.004127451
RBMS2 3.0 0.004531835
RNF114 3.0 0.004515209
ADARB1 3.0 0.00611204
CD68 3.0 0.005519366
HIST1H2BD 3.0 0.005945017
C5orf41 2.9 0.005125448
GCH1 2.9 0.004530075
BTN3A1 2.9 0.005318021
TNS1 2.9 0.004417939
PLA1A 2.9 0.004641544
PHF11 2.9 0.004863139
ZC3H12A 2.9 0.009125364
PHF11 2.9 0.00525
ELMO2 2.9 0.004530075
TMEM171 2.9 0.004890909
SLC2A5 2.9 0.013182957
ODF3B 2.9 0.005646853
RP2 2.9 0.004936594
SLC6A9 2.9 0.005976027
RHBDF2 2.9 0.004826007
SCO2 2.9 0.005292553
SOD2 2.9 0.025617444
HLA-H 2.9 0.023781475
RBM43 2.9 0.005761246
LY6E 2.8 0.006737013
HIST1H2AC 2.8 0.019658416
BTC 2.8 0.006158333
VCAM1 2.8 0.034578267
LAG3 2.8 0.005761246
VAMP5 2.8 0.005646853
TNFAIP3 2.8 0.007631579
LOC100134073 2.8 0.009993036
KRTAP1-3 2.8 0.00611204
PDCD1LG2 2.8 0.005862069
PATL1 2.8 0.005981229
PDE4B 2.8 0.006028912
LOC728946 2.8 0.006672131
ERAP2 2.8 0.020573218
PNPT1 2.8 0.006737013
SOD2 2.8 0.027360642
IL7R 2.7 0.014738889
NKX3-1 2.7 0.006672131
LOC653610 2.7 0.008442136
IFITM2 2.7 0.007198413
FTSJD2 2.7 0.006258278
DUSP5 2.7 0.00687299
NT5E 2.7 0.006737013
ETV7 2.7 0.006102694
DHRS9 2.7 0.028522167
BTN3A2 2.7 0.013046482
EDN1 2.7 0.009390935
CHEK2 2.7 0.016150964
AGRN 2.7 0.006870968
IFITM3 2.7 0.008192771
GRIP2 2.7 0.006361386
LOC100134304 2.7 0.019116766
C5orf41 2.7 0.007238924
ELF1 2.7 0.006899038
MOBKL2C 2.7 0.006820388
IFIT5 2.6 0.007124601
MUC1 2.6 0.007421136
LOC730996 2.6 0.007631579
SLC16A4 2.6 0.010586253
TGM2 2.6 0.007865854
YEATS2 2.6 0.007198413
C1QTNF1 2.6 0.019075
B3GNT2 2.6 0.007437107
LYPD1 2.6 0.013776596
PTN 2.6 0.008115502
HLA-A 2.6 0.01078
APOL6 2.6 0.007631579
AIDA 2.6 0.007631579
BCL2L13 2.6 0.007631579
PVRL2 2.6 0.007822086
RNF19B 2.6 0.007792308
TXNIP 2.6 0.008159091
CGNL1 2.6 0.008442136
LYPD1 2.6 0.014363426
IL7 2.6 0.009390935
LGALS8 2.6 0.007865854
ITGA2 2.5 0.008720588
NLRC5 2.5 0.008192771
RFX5 2.5 0.008285928
ADARB1 2.5 0.014709821
STAT3 2.5 0.008285928
SECTM1 2.5 0.008720588
CXCL9 2.5 0.009317529
PSMB9 2.5 0.010586253
LOC653631 2.5 0.008442136
HIST1H2BD 2.5 0.011361842
IL15 2.5 0.009598592
TMEM173 2.5 0.008841642
DCP1A 2.5 0.008720588
RNF149 2.5 0.010873016
MUC1 2.5 0.009317529
RBCK1 2.5 0.009317529
ARID5B 2.5 0.010096685
LOC653308 2.5 0.009135174
B4GALT5 2.5 0.009125364
GBP3 2.5 0.009390935
LOC390557 2.5 0.014917401
CHEK2 2.5 0.022642202
TLE4 2.5 0.009548023
LOC728951 2.5 0.009390935
N4BP1 2.5 0.010676944
C3orf38 2.5 0.009317529
RNF122 2.5 0.009390935
PGAM1 2.5 0.009859944
TRIM26 2.5 0.009796348
LOC730996 2.4 0.009867318
PSME1 2.4 0.010178571
NMI 2.4 0.012538071
FAM46A 2.4 0.013776596
C1S 2.4 0.029593949
TM4SF4 2.4 0.025310315
IRF9 2.4 0.012645202
CD274 2.4 0.010497275
SLFN12 2.4 0.010096685
RAB20 2.4 0.010096685
LOC728956 2.4 0.01030137
FAM111A 2.4 0.010165289
IL10 2.4 0.012139175
HLA-G 2.4 0.039740634
C3orf38 2.4 0.01045082
BAZ1A 2.4 0.011062005
LOC285047 2.4 0.010586253
PVRL2 2.4 0.010586253
SIGIRR 2.4 0.010873016
LOC147645 2.4 0.01078
C6orf188 2.4 0.010676944
CCDC109B 2.4 0.010873016
REC8 2.4 0.013776596
FAM111A 2.4 0.011364829
PLEKHH1 2.4 0.011914063
IL12A 2.4 0.012468112
SERTAD1 2.4 0.01138089
FST 2.4 0.013644802
TMEM189- 2.4 0.012139175
ATOH8 2.4 0.012538071
PML 2.4 0.011436031
RASD2 2.4 0.015393013
IL15 2.4 0.012139175
STOM 2.4 0.014230769
PGAM4 2.3 0.01230179
PPFIA4 2.3 0.01230179
ESM1 2.3 0.043651961
FSTL1 2.3 0.014561503
CYP2J2 2.3 0.014363426
NBN 2.3 0.012172237
FAM65B 2.3 0.023852679
SCARB2 2.3 0.012139175
HIAT1 2.3 0.013557214
FGF2 2.3 0.016703586
SFRP1 2.3 0.024916667
HAVCR2 2.3 0.012575949
TRIM69 2.3 0.013776596
C1S 2.3 0.0334
CENTA1 2.3 0.021174242
MTMR11 2.3 0.01302267
RBCK1 2.3 0.013648148
HLA-DPA1 2.3 0.027360642
NAMPT 2.3 0.014396552
SMARCA5 2.3 0.013260599
MAFB 2.3 0.013776596
LGALS8 2.3 0.013776596
CCND3 2.3 0.01323125
RORA 2.3 0.013762255
WSB1 2.3 0.0149117
STOM 2.3 0.01841785
PML 2.3 0.013579404
LOC100129566 2.3 0.013762255
ZNF702P 2.3 0.013776596
IRF7 2.3 0.014396552
B4GALT4 2.3 0.014805987
SPATA13 2.3 0.013776596
EFHD1 2.3 0.0372
LOC732371 2.3 0.013776596
LOC730052 2.3 0.01421729
RPS6KC1 2.3 0.013879108
TRIM5 2.3 0.013776596
DYNLT1 2.3 0.013776596
IFI30 2.3 0.027909699
ODF2L 2.3 0.01440367
PSMA4 2.3 0.013776596
STAT6 2.3 0.013776596
ADPRHL2 2.3 0.013762255
SNRPC 2.3 0.013776596
PTGS2 2.3 0.046594945
C19orf28 2.3 0.013814858
BMPR2 2.3 0.013776596
NFKBIA 2.3 0.020627395
PRKD1 2.3 0.014709821
DENND1A 2.3 0.01421729
C3AR1 2.3 0.013847059
HAS1 2.3 0.032449219
FST 2.2 0.018777666
USP42 2.2 0.014396552
ZFYVE20 2.2 0.014738889
GPR180 2.2 0.014690315
GNB4 2.2 0.014485126
CTSS 2.2 0.037602941
RBMS2P 2.2 0.014642045
LOC100133012 2.2 0.030416013
PGAM4 2.2 0.014690315
LOC645634 2.2 0.014503425
C19orf28 2.2 0.014709821
ALPK1 2.2 0.014643665
ANKIB1 2.2 0.014709821
LIPA 2.2 0.014643665
LOC100133489 2.2 0.03948913
ACSL5 2.2 0.015863931
PROCR 2.2 0.018103272
INSIG1 2.2 0.01511488
AXUD1 2.2 0.01488385
GNA13 2.2 0.016353945
C7orf42 2.2 0.01511488
CXorf38 2.2 0.014961538
OTUD4 2.2 0.015701087
RPS6KC1 2.2 0.015822511
INSIG1 2.2 0.015748373
ANKFY1 2.2 0.016414894
TNFRSF14 2.2 0.01654334
LOC732007 2.2 0.015697168
OAS1 2.2 0.015975216
SPATS2L 2.2 0.016075269
LOC728946 2.2 0.028926256
LOC643384 2.2 0.016314103
PI4K2B 2.2 0.016427813
ZFP36L2 2.2 0.017942387
APOBEC3D 2.2 0.016150964
ZNF350 2.2 0.017525988
PDGFRL 2.2 0.021174242
FLT3LG 2.2 0.016959034
SOCS1 2.2 0.017639463
SQRDL 2.2 0.019568452
LOC255620 2.2 0.016525424
CCRL1 2.2 0.021365348
SIX1 2.2 0.017369792
B2M 2.2 0.018084016
JUNB 2.2 0.029593949
CHMP5 2.2 0.017942387
TRIM56 2.2 0.017201883
RGS20 2.2 0.043150492
MCL1 2.2 0.020639313
CD82 2.1 0.022009259
SAMHD1 2.1 0.018649194
EID3 2.1 0.020605769
WSB1 2.1 0.018401222
SOCS2 2.1 0.020427308
KIAA1751 2.1 0.040046695
BNIP3 2.1 0.017614108
CEBPD 2.1 0.022051756
TSKU 2.1 0.018362245
PSMA4 2.1 0.0176294
MOCOS 2.1 0.021957328
WSB1 2.1 0.020627395
RAB43 2.1 0.01841785
PSMF1 2.1 0.018084016
CAPN3 2.1 0.022642202
H1F0 2.1 0.022974453
USF1 2.1 0.01944831
PYCARD 2.1 0.018649194
KLF6 2.1 0.020497104
IL15RA 2.1 0.020455882
COMMD10 2.1 0.018992986
ZFYVE26 2.1 0.018649194
RABGAP1L 2.1 0.018825301
GRINA 2.1 0.020931559
WISP1 2.1 0.030970266
PCDH17 2.1 0.020497104
SCML1 2.1 0.019881423
TAPBP 2.1 0.02185514
BMPR2 2.1 0.019143426
STAT3 2.1 0.020187008
PDZD2 2.1 0.027360642
SNORD89 2.1 0.029593949
GADD45B 2.1 0.020497104
SYNM 2.1 0.020497104
LIMA1 2.1 0.020497104
TRADD 2.1 0.020044379
L2HGDH 2.1 0.020497104
SLC30A1 2.1 0.020639313
PCGF5 2.1 0.020814286
SPPL2A 2.1 0.023903197
GCNT1 2.1 0.042553041
SLC39A14 2.1 0.046248285
BDNF 2.1 0.023601083
MYCBP2 2.1 0.021474719
LOC100130308 2.1 0.020497104
C12orf31 2.1 0.020497104
NAMPT 2.1 0.027981728
KCNS3 2.1 0.027285959
PGAM4 2.1 0.021365348
NAPA 2.1 0.021474719
PRKD2 2.1 0.021908752
PML 2.1 0.021861007
TJP1 2.0 0.021423872
RGMB 2.0 0.024766725
LOXL3 2.0 0.025568576
FAM125B 2.0 0.021365348
BTN3A2 2.0 0.023053539
GRINA 2.0 0.022449262
CX3CL1 2.0 0.036451493
PPP2R2A 2.0 0.021957328
MCL1 2.0 0.022642202
ETV3 2.0 0.029601106
SERPINB1 2.0 0.023031818
ATP8B4 2.0 0.048101351
SP100 2.0 0.023852679
GBP6 2.0 0.023852679
TINF2 2.0 0.022783883
IL15RA 2.0 0.023903197
GTF2B 2.0 0.022966179
MR1 2.0 0.02478471
ACOT7 2.0 0.023442029
LAYN 2.0 0.023601083
PIM1 2.0 0.027360642
PGAM1 2.0 0.023031818
HLA-DOB 2.0 0.024598057
P2RY5 2.0 0.028522167
TRAF3IP2 2.0 0.03948913
DNAJA1 2.0 0.024233156
LOC100131091 2.0 0.023657658
RAD9A 2.0 0.023852679
MAT2B 2.0 0.027360642

